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Triple-negative breast cancer (TNBC) is characterized by genomic heterogeneity and high risk of 
relapse. Recent studies have demonstrated that breast cancers can contain a spectrum of epithelial and 
mesenchymal phenotypes. We identified epithelial (POS) and mesenchymal (NEG) subpopulations in a 
triple negative breast cancer cell line that have similar coding sequences, but unique enrichment of the 
epigenetic activators H3K27ac and BRD4. We show that localization of these epigenetic activators 
correlates with the expression of epithelial transcription factors TP63 and ELF3 in epithelial cells, and 
ZEB1 and TWIST1 in mesenchymal cells. Currently, there are no targeted therapies available for the 
treatment of triple negative breast cancer. However, overexpression of EGFR, KRAS, or BRAF occurs in 
approximately 30% of TNBC, suggesting that inhibiting the MAPK signaling pathway may be an effective 
therapy for TNBC. Acute treatment with the MEK inhibitor trametinib induced distinct transcriptional 
responses in epithelial and mesenchymal subpopulations. ChIP-Seq analysis of H3K27ac and BRD4 
binding revealed epigenetic remodeling in response to trametinib treatment, especially at binding sites for 
AP-1 in NEG cells and epithelial-specific ETS transcription factors in POS cells. Chronic treatment with 
trametinib induced the emergence of trametinib resistant POS cells, but not NEG cells. In trametinib 
resistant POS cells, we observe increased expression of the Gi-coupled chemokine receptor CXCR7, and 
its cognate ligand adrenomedullin, as well as increased expression of KRAS. ChIP-Seq analysis revealed 
enrichment of H3K27ac and BRD4 at the CXCR promoter and enhancer, indicating epigenetic remodeling 
induces transcriptional activation. siRNA knockdown of CXCR7 and KRAS demonstrate these genes are 
essential for the proliferation of trametinib resistant cells, and reveals that epigenetic remodeling at the 
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CHAPTER 1: BREAST CANCER SUBTYPES AND CURRENT THERAPIES 
Kinases have been recognized as highly tractable targets for cancer treatment due to their 
druggability and the critical roles they play in regulating cellular growth, differentiation, migration, and 
survival. There are currently 28 FDA-approved kinase inhibitors (P. Wu et al., 2016), with many more in 
various stages of clinical trials. Successful kinase inhibitor clinical trials in cancer patients have targeted 
kinases that are mutated or overexpressed and where additional preclinical evidence demonstrates that 
the target kinase is sufficient to drive disease pathology. For example, mutant BRAF in melanoma can be 
targeted with the FDA approved targeted kinase inhibitors vemurafenib and dabrafenib. Similarly, EGFR 
mutations are targeted in non-small cell lung tumors using the kinase inhibitors gefitinib and erlotinib. 
However, comprehensive sequencing studies have revealed that unlike many cancers, the landscape of 
the breast cancer genome is characterized by few oncogenic mutations, and is instead dominated by 
copy number variants and somatic copy number aberrations. Whole exome sequencing of 507 breast 
tumors by the TCGA identified somatic mutations in only three genes with greater than 10% incidence 
rate: TP53, PIK3CA, and GATA3 (Cancer Genome Atlas Network, 2012). Analysis of 2,000 breast tumors 
demonstrated that somatic copy number aberrations alter expression of approximately 40% of tumor 
genes (Curtis et al., 2012), but the role of these copy number variants and somatic copy number 
aberrations in tumorigenesis remains unclear. Therefore, identifying candidate kinases to target in breast 
tumors has proven difficult given the lack of dominating mutations in signaling pathways that have the 
potential to drive disease progression. 
Breast cancer is a heterogeneous disease and molecular characterization of tumors has defined 
five distinct subtypes that are associated with different prognoses including luminal A, luminal B, HER2-
enriched, basal-like and claudin-low (Perou et al., 2000; Prat et al., 2010). Interrogation of the breast 
cancer genome and transcriptome has identified genes that are uniquely altered across the molecular 
subtypes that represent potential targets for therapeutic intervention. For instance, luminal A and B 
subtypes typically express the estrogen (ER) and/or progesterone (PR) receptors which can be targeted 
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with hormone therapy. Additionally, notable success has been achieved in HER2-enriched tumors by 
targeting the HER2 receptor tyrosine kinase (RTK) with monoclonal antibodies and small molecule 
inhibitors. However, basal-like and claudin-low subtypes are defined as triple negative breast cancer 
(TNBC) due to the absence of targetable ER, PR, and HER2 receptor expression. A multiplatform 
analysis across over 3,500 specimens and twelve tumor types found that breast cancer specimens fell 
into two groups where luminal and HER2-enriched tumors clustered away from basal-like specimens 
(Hoadley et al. 2014). Furthermore, comparison across all twelve tumor types revealed that basal-like 
tumors were more similar to lung cancer than they were to luminal and HER2-enriched tumors. These 
data support the notion that triple negative breast cancer encompasses a unique disease state. This vast 
heterogeneity of breast cancer has deterred the identification of targetable kinases driving disease 
pathology across breast cancer, and as a result ongoing studies are focusing on defining therapeutic 
targets within each subtype of breast cancer in order to develop customized therapies for each subtype. 
This chapter discusses the genomic landscape of the kinome in breast cancer subtypes, kinase inhibitors 
being investigated in clinical trials.  
 
Genomic Analysis of the Breast Cancer Kinome 
Luminal Breast Cancer 
Tumors classified in the luminal A molecular subtype contain the fewest defined mutations, but 
exhibit high mutational frequency in a select number of genes including PIK3CA at 44%, followed by 
MAP3K1 (13%), and MAP2K4 (7%) (Figure 1A and B). Luminal A tumors are typically dependent on ER 
activation for proliferation, and are responsive to hormone therapy. Pathway analysis of luminal breast 
cancer revealed FOXA1-ER as an essential signaling hub in luminal tumors, and hazard models indicate 
that low expression of FOXA1 improves prognosis in luminal A breast cancer patients (Badve et al., 
2007). High frequency of PIK3CA mutations suggests activation of the AKT signaling pathway, but 
PIK3CA mutations do not significantly increase phosphorylation of biomarkers for PIK3CA activation 
including AKT, ribosomal protein S6 or 4EBP1, suggesting compensatory feedback regulatory 
mechanisms are controlling activity of the pathway in luminal breast cancers. This contrasts with PIK3CA 
mutation or amplification in HER2-enriched tumors and PTEN or INPP4B loss in basal breast cancers, 
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Figure 1. Overview of the genomic landscape across breast cancer molecular subtypes. (A) Kinome trees highlighting mutations 
and copy number alterations found in each subtype of breast cancer.  (B) Mutation frequencies in kinase-driven signaling pathways 
across breast cancer subtypes. Mutation frequencies for each molecular subtype were calculated using the whole genome 
sequencing data in the TCGA study following PAM50 classification available via cBio Portal (Cancer Genome Atlas Network, 2012; 
Cerami et al., 2012). Frequencies of mRNA overexpression in breast cancer molecular subtypes were calculated using a two-fold 




where increased phosphorylation of these biomarkers is observed (Cheng et al., 2015). Luminal A tumors 
also harbor inactivating mutations of MAP3K1 (13%) and MAP2K4 (7%), which regulate JNK and p38 
activation (Figure 1B). A hypothesis for the functional role of MAP3K1 and MAP2K4 inactivating 
mutations in luminal A tumors is their role during mammary gland involution, which involves post-
lactational apoptosis and tissue remodeling (Avivar-Valderas et al., 2014). Delay or failure of involution is 
a breast cancer risk factor, possibly because failure of involution could allow cancer progenitor cells to 
survive.  
Luminal B tumors exhibit a higher diversity of mutations than the Luminal A molecular subtype, 
which occur at lower frequency, with TP53 and PIK3CA being the most frequent at 29%. In addition, the 
majority of luminal B tumors are clinically characterized by expression of the ER (82%), but a subset of 
tumors (11%) also express the HER2 receptor. Pathway analysis of Luminal B tumors revealed that 
proliferation is driven by the transcriptional activity of MYC and FOXM1. Copy number analysis of luminal 
B tumors confirms amplifications of CCND1, CDK4, and CDK6, which suggests dysregulation of cell cycle 
progression in G1. Amplifications were also found in several members of the FGFR receptor family and 
IGFR1. Mutually exclusive inactivating mutations were also observed in MAP3K1 (5%) and MAP2K4 
(2%), at a lower frequency compared to luminal A tumors (Figure 1B).  
HER2-enriched Breast Cancer 
The HER2 molecular subtype has a high frequency of HER2-amplification (72%) and PIK3CA 
mutation (38%), but few other kinase and non-kinase genes are significantly mutated in this subtype 
(Figure 1A and B). Gene expression analysis of HER2 tumors revealed elevated expression of FGFR4, 
EGFR, and HER2, as well as several other genes in the HER2 amplicon. Copy number analysis of HER2 
tumors revealed frequent loss of PTEN and INPP4B, contributing to activation of PI3K-AKT-mTOR 
signaling in HER2-enriched tumors. Amplification of members of the FGFR receptor family, EGFR, CDK4 
and cyclin D1 also highlight several potentially targetable kinases. Reverse Phase Protein Array (RPPA) 
analysis revealed increased phosphorylation of HER2 and EGFR, in addition to elevated phosphorylation 





Basal-like Breast Cancer 
A large subset of basal-like breast cancer is characterized by TP53 mutation or loss (78%), but 
this subtype is otherwise devoid of significant somatic mutations, with the only other frequent mutation 
being PIK3CA (7%) (Figure 1A and B). Gene expression analyses found the basal-like subtype is 
characterized by an elevated cell proliferation signature, as well as the expression of basal keratins 5, 6, 
and 17. Pathway analysis of basal-like breast cancer identified hyper-activated MYC and HIF1a as key 
transcription factors controlling the basal-like phenotype. Copy number analysis indicates activation of 
PI3K signaling through deletion of PTEN and INPP4B. Elevated expression is observed for PIK3CA 
(18%), KRAS (7%), BRAF (15%) and EGFR (19%). Several RTKs are also amplified in basal-like tumors, 
including FGFR1, FGFR2, IGF1R, KIT, MET and PDFGRA. The high proliferation signature in basal-like 
breast cancer suggests that these tumors are highly responsive to anti-mitotic chemotherapy, but a lack 
of dominating therapeutic targets and high tumor diversity makes basal-like breast cancer difficult to treat. 
Claudin-low Breast Cancer 
While claudin-low tumors are similar to basal-like tumors in being triple negative for ER, PR and 
HER2, the claudin-low molecular subtype lacks the proliferation gene signature characteristic of basal-like 
breast cancers. Furthermore, immunohistochemical analysis of claudin-low tumors revealed depletion of 
cell-cell adhesion genes claudin-3 and E-cadherin relative to other molecular subtypes indicating that 
these cells exhibit a mesenchymal phenotype (Prat et al., 2010). Claudin-low cells also have elevated 
expression of genes characteristic of mesenchymal cells including AXL and ZEB1. Claudin-low tumors 
are also enriched in genes involved in sensing and regulating the extracellular matrix, including the 
collagen receptor DDR2, and integrin alpha 5. 
 
Kinase Inhibitors Targeting Breast Cancer Molecular Subtypes 
Despite FDA approval of targeted therapies for the luminal and HER2-amplfied subtypes, breast 
cancer remains a leading cause of cancer-related mortality among women. Expression of the ER and PR 
in luminal A and B subtypes of breast cancer provide targets for hormone therapies including tamoxifen, 
which blocks the ability of estrogen to interact with its receptor, and aromatase inhibitors which block the 
production of estrogen. The HER2 receptor can be targeted in HER2-enriched breast cancer using the 
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monoclonal antibodies trastuzumab or pertuzumab, or the small molecule inhibitor lapatinib, which block 
activation of HER2 and other ERBB family RTKs. However, the majority of basal-like and claudin-low 
tumors are pathologically classified as triple negative breast cancer (TNBC) and do not express the ER, 
PR or HER2. Given their negative receptor status, there are currently no FDA-approved targeted 
therapies for TNBC. However, several kinase-driven growth promoting signaling pathways are 
dysregulated in TNBC including the RAF-MEK-ERK signaling cascade (Figure 1B), offering potential new 
targets for the treatment of TNBC. A complete list of kinase inhibitors that are FDA-approved or currently 
in clinical trials can be found on the following page in Table 1. 
HER2 targeted therapies 
HER2 is an ERBB-family RTK that is commonly overexpressed in tumors in the HER2-enriched 
molecular subtype. HER2 acts a co-receptor for several ligands resulting in the formation of heterodimers 
with other ERBB family members, such as HER3 and EGFR to stimulate PIK3CA and MAP Kinase 
pathway activation. Trastuzumab is a humanized monoclonal antibody that binds to the extracellular 
domain of HER2, preventing ligand-independent activation of the HER2 receptor and eliciting an immune 
response that results in antibody-dependent cytotoxicity in HER2-positive tumor cells. Early clinical trials 
of trastuzumab in combination with chemotherapy reported increased time to disease progression (7.4 vs 
4.6 months) and increased rate of objective response (50% vs 32%) compared to the control arm of the 
study (Slamon et al., 2009). A four year follow up across multiple studies further illustrated the efficacy of 
trastuzumab treatment in HER2-amplfied patients with a 39% reduction in death rate (Perez et al., 2011). 
As a result, trastuzumab has become the standard of care for women with HER2-enriched breast cancer. 
Sequencing studies have demonstrated that EGFR, a co-activator of HER2, is often overexpressed or 
amplified in HER2-enriched breast cancer. Therefore, combining trastuzumab with EGFR inhibitors may 
have a clinical benefit for HER2 patients with EGFR overexpression. Indeed, recent clinical studies have 
determined that co-treatment with trastuzumab and the dual EGFR/HER2 inhibitor lapatinib enhances 
response in patients (Blackwell et al., 2012). Preclinical studies have demonstrated that HER3 is a potent 
co-activator of HER2 signaling, which can stimulate activation of MAP kinase and PIK3CA pathways. 




Table 1. Targeted Kinase Inhibitors for the Treatment of Breast Cancer (FDA-Approved or in Clinical Trials).  
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transactivation of HER2 and HER3 receptors (Capelan et al., 2013). Notably, dimerization of HER2 with 
HER3 has been published as a major mechanism of resistance to HER2 kinase inhibitors, (N. Dey et al., 
2015) and a multicenter clinical trial established significant benefit adding pertuzumab to trastuzumab in 
patients whose disease had progressed during prior trastuzumab treatment (Baselga et al., 2010). 
Neratinib is an additional targeted inhibitor that irreversibly binds to multiple members of the HER family 
including EGFR, HER2 and HER4. Recent results of the ExteNET trial demonstrate that neratinib can be 
used to extend adjuvant treatment of HER2-positive patients previously treated with trastuzumab (A. 
Chan et al., 2016). Additionally, Puma Biotechnology has reported a significant increase in disease free 
survival with a 33% reduced risk for invasive disease recurrence with neratinib treatment compared to 
placebo.  
PI3K/mTOR pathway inhibitors 
Components of the phosphatidylinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) 
pathway are also commonly dysregulated in multiple subtypes of breast cancer (Figure 1B) making AKT, 
PI3K, and mTOR promising kinase targets for treatment. Upon RTK activation, the p85 regulatory subunit 
of PI3K binds to the phosphorylated RTK, and recruits the p110 catalytic subunit to the cell membrane, 
where it phosphorylates phosphatidylinositol 4,5 bisphosphate (PIP2) at the 3’ position. Phosphorylation of 
PIP2 recruits PDK1 to the membrane, where it phosphorylates and activates AKT to stimulate proliferation 
and survival. Activating mutations in PIK3CA or deletion of the PI3K antagonists PTEN and INPP4B 
phosphatases increases AKT activation, which results in cell cycle progression and inhibition of pro-
apoptotic Bcl-2 family proteins. Therefore, targeting the PI3K signaling pathway to prevent survival of 
resistant tumors may sensitize patients that were previously unresponsive to therapy. The BOLERO-2 
clinical trial found that treatment using the mTOR inhibitor everolimus in combination with an aromatase 
inhibitor improved progression free survival by more than two fold in hormone receptor-positive, HER2-
negative patients otherwise refractory to aromatase inhibitor therapy (Piccart et al., 2014). The phase II 
TAMRAD study similarly determined that patients resistant to endocrine therapies were more sensitive to 
combination treatment with everolimus (Bachelot et al., 2012). Given these results, the combination of 
everolimus and aromatase inhibitors has been approved for treatment of advanced stage, ER-
positive/PR-positive/HER2-negative patients. HER2-enriched breast cancers also have a high frequency 
 
9 
of activating mutations in PIK3CA (38%), and studies have shown that PIK3CA mutations correlate with 
significantly lower complete response rates in HER2-enriched patients treated with trastuzumab (Loibl et 
al., 2014). These results suggest that targeting PI3K signaling in HER2-enriched patients may improve 
response of tumors with mutant PI3KCA. The BOLERO-3 trial found that the addition of everolimus to 
trastuzumab significantly prolonged progression free survival in patients otherwise insensitive to 
trastuzumab (Andre et al., 2014). Similar clinical results have been found for treatment of HER2-amplfied, 
ER-positive and PR-positive patients with the mTOR inhibitor temsirolimus. Several phase II and phase III 
clinical trials found that the addition of temsirolimus to endocrine or HER2 targeted therapies only 
benefited heavily pretreated women and had little effect on cohorts of women naïve to treatment (S. Chan 
et al., 2005; Fleming et al., 2012; Wolff et al., 2013). Everolimus is also being tested in triple negative 
patients (NCT01939418). Additionally, inhibitors targeting downstream effectors of the pathway including 
AKT (MK2206 and GSK2141795) and PI3K (BKM120) are currently in clinical trials as single agents and 
in combination with other currently approved drugs in all subtypes of breast cancer.  
MAPK pathway inhibitors 
The mitogen activated protein kinase (MAPK) pathway plays an essential role in normal cell 
proliferation and differentiation, and dysregulation of this pathway has been shown to contribute to many 
different kinds of cancer. Members of the MAPK pathway are also aberrantly expressed and mutated in 
breast cancer. Triple negative breast cancer patients in particular show overexpression of members of the 
MAPK pathway including KRAS and BRAF (Figure 1B). Chemotherapy remains the only approved 
therapy for TNBC patients due to the absence of ER, PR and HER2 expression. It is therefore important 
to develop targeted therapies for TNBC. Overexpression of KRAS and BRAF in TNBC may stimulate 
MAPK pathway activation, which can be targeted by inhibition of downstream effector kinases. There are 
several ongoing clinical trials studying the benefit of treating advanced TNBC patients with MEK inhibitors 
including trametinib, selumetinib and binimetinib. Preclinical studies have also suggested that combined 
inhibition of the MAPK and PI3K/mTOR pathways could be beneficial to breast cancer patients by 
preventing adaptive resistance mechanisms to single inhibitor therapy (Saini et al., 2013). Trials have 
assessed the safety of combined MEK inhibition with PI3K or AKT inhibitors in multiple types of cancer 
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(NCT01138085, NCT01476137, NCT01562275, NCT01363232) and clinical trials are ongoing to test the 
efficacy of this combination therapy in advanced breast cancer (NCT01390818).  
Receptor Tyrosine Kinase Inhibitors 
There are several other RTKs that have been identified as drivers of disease progression in 
breast cancer subtypes. These RTKs also have the potential to activate alternative signaling pathways to 
drive resistance to single inhibitor treatments. Clinical trials are ongoing to assess treatment of HER2-
enriched tumors with the IGF-1R/IR inhibitor BMS-754807 (NCT00788333). The IGF-1R inhibitor 
cixutumumab was recently evaluated in a phase II clinical trial in combination with endocrine therapy 
(Gradishar et al., 2016). The results of this study showed little additive effect of combination cixutumumab 
treatment with endocrine therapy and IGF1-R expression did not correlate with patient response to 
therapy. However, mRNA analysis revealed that low expression of total insulin receptor resulted in 
improved progression free survival regardless of treatment. Cixutumumab has also been evaluated in 
combination with the targeted mTOR inhibitor temsirolimus in a phase I clinical study (Ma et al., 2013), 
and the efficacy of combination cixutumumab and temsirolimus treatment in locally recurrent or metastatic 
breast cancer is ongoing in a phase II clinical trial (NCT00699491). 
Preclinical studies have defined additional kinase targets amplified or activated in triple negative 
breast cancers including EGFR, VEGFR, PDGFR and SRC family kinases. EGFR is overexpressed in 
19% of basal-like breast cancer, which suggests that these tumors may be sensitive to EGFR inhibitors, 
but initial clinical trials with EGFR inhibitors have been disappointing. One potential explanation for the 
failure of EGFR inhibition in clinical trials is a lack of criterion for identifying EGFR amplification in 
patients. Additionally, clinical trials have evaluated combining multiple RTK inhibitors in metastatic breast 
cancer patients. A phase II trial found little additive effect of combining the VEGFR inhibitor bevacizumab 
with erlotinib, but this study was performed in unselected patients (Dickler et al., 2008). These studies 
highlight the need for biomarker analysis in future clinical studies in order to identify breast cancer 
patients likely to respond to targeted inhibition of RTKs. 
Several kinase inhibitors of the VEGF receptor have been studied in treating multiple breast 
cancer subtypes. VEGFR is an essential regulator of angiogenesis, which is necessary to support tumor 
growth. Angiogenesis is also necessary for the progression of metastasis making VEGF receptors 
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potential therapeutic targets. Several clinical trials have investigated the efficacy of adding the 
monoclonal anti-VEGFR antibody bevacizumab to standard chemotherapy in hormone receptor negative 
patients (Cobleigh et al., 2003; Lang et al., 2012; K. D. Miller et al., 2005; Robert et al., 2011). The results 
of these studies have been varied with several initial clinical trials showing significantly improved 
progression free survival in TNBC patients treated with bevacizumab. More recent trials have failed to 
show improved survival in estrogen receptor negative cohorts and the FDA approval of bevacizumab in 
breast cancer patients was ultimately withdrawn due to lack of efficacy with increased toxicity of 
treatment. Several other kinases inhibitors targeting VEGF receptors in TNBC are still being evaluated in 
clinical trials, including the broad-acting inhibitors sunitinib (NCT00887575) and sorafenib 
(NCT00825734, NCT00544167).  
Despite the initial promise of kinase inhibitors for the treatment of many cancers, these therapies 
often fail due the emergence of drug resistance after a pathological partial response. Recent studies have 
shown that this resistance can be caused by epigenetic remodeling that enhances the transcription of 
genes to stimulate pathway reactivation in the presence of the drug, or activate parallel signaling 
pathways that promote survival. Chapter 2 will briefly overview the genetic and epigenetic factors that 





CHAPTER 2: HUMAN TRANSCRIPTIONAL REGULATION IN CANCER 
The human genome contains the genetic information for all cells, and it is simply the 
interpretation and expression of the genome that determines cell identity. Therefore, gene expression is 
highly regulated during development to control differentiation and fate. This requires multiple layers of 
regulation that can activate or repress transcription either temporarily or permanently. This chapter will 
briefly overview the regulatory elements involved in human transcriptional regulation in normal 
development and oncogenesis. 
 
DNA Regulatory Elements in Mammalian Transcription 
There are two regulatory elements encoded in the DNA: a core promoter region that recruits RNA 
Polymerase II (RNAPII) to the transcription start site (TSS), and an enhancer region that recruits 
transcriptional activators (Figure 2). The core promoter is an approximately 100 bp region surrounding the 
TSS at the 5’ end of the target gene, which typically contains a TATA-box binding sequence 
<TATAa/tAa/t> positioned -25 to -30 bp from the TSS, and a pyrimidine-rich initiator sequence 
<YYANt/aYY> near the TSS (Javahery et al., 1994; Nakajima et al., 1988). These sequences recruit the 
pre-initiation complex (PIC), and determine the orientation and position of transcriptional initiation 
(Roeder, 1996). However, core promoter regions demonstrate low basal transcriptional activity and are 
often insufficient to reach maximal transcriptional output from the target gene. Novel sequencing 
techniques, along with advances in computational biology have demonstrated that distal enhancer 
regions amplify the transcriptional activity of core promoter regions (Stadhouders et al., 2012). Enhancers 
are large regulatory regions that bind transcription factors and interact with subunits of the Mediator 
complex to help recruit RNAPII to the target gene and increase transcriptional output. Enhancers are 
several hundred kilobases in length, and typically found in intergenic regions. These regions cooperate 
with promoters to regulate gene expression during differentiation and development to control cell fate and 




Figure 2: Enhancer Regulation of Mammalian Transcription1. (1) Transcription factors and transcriptional co-activators, bind the 
promoter and enhancer regions of the target gene, and recruit histone acetyltransferase p300. (2) Increased H3K27ac recruits 
additional transcriptional co-activators such as BRD4 to promoter and enhancer region, DNA loops to bring enhancer proximal to the 
target gene promoter. (3) Mediator complex binds transcriptional co-activators, and the PIC and RNAPII bind the promoter region, 





                                                   
1 Illustration adapted from (Soutourina, 2018) 
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Role Chromatin Structure in the Regulation of Gene Expression 
The transcriptional activity of promoter and enhancer regions is tightly regulated by chromatin 
structure and histone modifications that are established early in development. Nucleosome packing and 
higher-order chromatin structures play essential roles in the regulation of gene expression and cell 
identity. Genome-wide assessment of chromatin structure identified an inverse correlation between 
nucleosome occupancy and transcriptional activity, indicating that DNA is most accessible in regions of 
active transcription (C.-K. Lee et al., 2004). Additionally, the regulation of chromatin structure plays a key 
role in development and the maintenance of differentiation state. Studies of the regulation of chromatin 
structures in embryonic stem cells revealed that these cells have relaxed and permissive euchromatin 
that is maintained by the chromatin remodeling factor CHD1 (Gaspar-Maia et al., 2009). Depletion of 
CHD1 results in the accumulation of heterochromatin and loss of pluripotency, suggesting that the 
maintenance of euchromatin is essential in embryonic stem cells. Furthermore, a survey of six different 
human cell types revealed a unique chromatin fingerprint for each cell type, indicating that chromatin 
structure plays an essential role in the maintenance of identity (Ernst and Kellis, 2013).  
Higher-order chromatin structure regulates gene expression by controlling the proximity of 
enhancers and core promoter regions in specific cell types. Chromatin looping helps maintain specificity 
of active enhancer regions for their cognate promoter and insulate the target genes from improper 
interactions (Hnisz et al., 2016). Analysis of chromatin structure using chromatin conformation capture 
demonstrates that chromatin is partitioned into topological association domains (TADs) that 
conformationally restrict the binding of promoters and enhancer regions (Zabidi and Stark, 2016). These 
TADs are observed in all cell types and evolutionarily conserved, and disruption of these domains leads 
dysregulation of gene expression, suggesting this a fundamental method of transcriptional regulation. The 
boundaries of these domains are defined by insulator proteins such as CCCTC-binding factor (CTCF), 
which stabilize loop formation and control the propagation of histone marks. CTCF recruits cohesin, which 
binds the ends of the chromatin loop to stabilize the TAD. Depletion of either CTCF or cohesin disrupts 
chromatin loop formation and results in gene dysregulation, indicating that the CTCF and cohesin are 




Role of DNA Methylation in Transcriptional Regulation 
DNA methylation is a heritable epigenetic modification of cytosine-guanine dinucleotides (CpG) 
that is enriched in heterochromatin and observed in the promoter region of transcriptionally silenced 
genes (Jones and Takai, 2001). CpG dinucleotides are distributed throughout the genome, but highly 
enriched in regions called CpG islands, which are found in the promoter region of 60-70% of human 
genes. DNA methyltransferases (DNMTs) catalyze the conversion of cytosine to 5-methyl cytosine by 
transferring a methyl group from the donor S-adenosyl-L-methionine to the 5th carbon of the cytosine 
base. DNMT1 is considered a maintenance methyltransferase because it has high affinity for hemi-
methylated DNA strands, and catalyzes the methylation of cytosine during DNA replication (Biswas and 
Rao, 2017). In contrast, DNMT3A and DMNT3B have higher affinity for unmethylated DNA, and deposit 
de novo methylation at CpG islands. Methylation of CpG islands recruits methyl binding proteins that can 
exclude transcriptional activators and silence transcription. 
 
Role of Histone Modifications in Transcriptional Regulation 
The N-terminal tails of histones can be post-translationally modified to regulate chromatin 
structure and transcriptional activity of the target locus. There are three general classes of histone 
modifications: methylation, acetylation, and phosphorylation. The position of each of these modifications 
on a specific histone isoform creates a code that can be interpreted by histone binding proteins to activate 
or repress transcription. The histone code is incredibly complex, with each histone having unique 
modifications that regulate transcription at specific developmental stages or at certain regions genome. 
Therefore, for simplicity, I’ll review the most well studied histone modifications that regulate transcription 
in normal and tumorigenic cells. Methylation of the N-terminal tail of histone H3 at lysine 4 (H3K4) is 
catalyzed by histone methyltransferases (HMTs) at enhancers and core promoter regions associated with 
poised or actively transcribed genes. H3K4 can be methylated by a family of SET domain containing 
HMTs including SET1A, SET1B, MLL1, MLL2, MLL3, MLL4, SMYD1, SMYD2, SET7/9 and PRDM9 
(Hyun et al., 2017). Crystal structures of SET domain family members demonstrate that the SET domain 
catalyzes methyl transfer by binding the histone substrate and stabilizing the methyl donor S-adenosyl-L-
methionine (Dillon et al., 2005). Methylation of histones is a reversible modification, which allows the cell 
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to finely tune the histone code and differentially regulate gene expression during development. 
Methylation at H3K4 can be removed by the lysine demethylases KDM1A, KDM1B, KDM5A, KDM5B, 
KDM5C, KDM5D, and RIOX1 (Hyun et al., 2017). It remains unclear, however, the mechanism by which 
histone methyltransferases and demethylases recognize specific genomic loci for catalysis. ChIP-Seq for 
H3K4 methylation identified an enrichment for H3K4 monomethylation (H3K4me1) at enhancer regions 
associated with active or poised gene transcription, whereas H3K4 trimethylation (H3K4me3) is a 
hallmark of the promoter region of actively transcribed or poised genes (Heintzman et al., 2009). Histone 
trimethylation of histone H3 also occurs at lysine 27 (H3K27me3), which is transferred by the SET domain 
methyltransferases EZH1 and EZH2. H3K27me3 is primarily a repressive histone modification, which is 
observed in promoter regions associated with transcriptionally silenced genes and enriched in methylated 
CpG islands. However, H3K27me3 is also observed with H3K4me1 at enhancer and promoter regions of 
genes poised for transcription. These bivalent promoter regions are essential to the regulation of 
differentiation because they allow the target gene to remain poised for activation but transcriptionally 
silent in the absence of a differentiation signal (Creyghton et al., 2010). Gene silencing by H3K27me3 is 
antagonized by the transfer of an acetyl group from acetyl-CoA to histone H3 lysine 27 (H3K27ac) by the 
histone acetyltransferases CBP and p300 (Tie et al., 2009). Acetylation at H3K27 is reversible and can be 
removed by a family of enzymes called histone deacetylases (HDACs). ChIP-Seq analysis of H3K27ac 
identified enrichment at enhancers and core promoter regions of actively transcribed genes, and was 
highly correlated with p300 binding. Chromatin accessibility assays following acetylation of H3K27 
indicate that acetylation induces chromatin relaxation and a permissive chromatin state that increases 
binding of transcriptional co-activators such as the histone acetylation reader BRD4 (Mueller et al., 2017). 
These results indicate that p300 binding increases H3K27ac at enhancers and core promoter regions to 
activate transcription. Furthermore, several studies demonstrate that transcription factors can bind and 
recruit p300 to acetylate specific DNA sequences in activated enhancer regions (Alver et al., 2017; Rubin 
et al., 2017; Zabidi et al., 2015). Histone acetylation readers such as BRD4, can bind acetylated histones 
to recruit Mediator and PIC to enhance transcription at sites of H3K27ac (Jang et al., 2005). BRD4 can 
also bind transcription factors for locus-specific localization of transcriptional co-activators to enhance 
transcription of target genes (S.-Y. Wu et al., 2013). In this manner, cells can control histone methylation 
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or acetylation to modulate the activity of enhancers and promoters to control transcription during 
development and maintain cell identity.  
 
Epigenetic Dysregulation in Cancer 
The regulation of chromatin structure and modification is essential to normal development and 
differentiation, but can become dysregulated during tumorigenesis. While normal development requires 
tight regulation of chromatin structure and histone marks, these regulatory mechanisms can be used by 
cancer cells to silence the expression of tumor suppressors and activate the expression of oncogenes. 
Whole exome sequencing of diverse tumor types identified mutations in the SWI/SNF chromatin 
remodeling complex in greater than 20% of cancers (Kadoch and Crabtree, 2015). These mutations can 
affect either localization or activity, leading to dysregulation of nucleosome positioning and gene 
transcription. Mutations in the SWI/SNF chromatin remodeling complex prevents nucleosome eviction of 
H3K27me3 histones at the CDKN2A locus, which silences p16 expression and increases proliferation 
(Wilson et al., 2010). Additionally, expression CDKN2A can be silenced by DNA methylation, which has 
been shown to increase at the CDKN2A locus during progression of lung cancer from lung airway basal 
cell hyperplasia (17%) to squamous metaplasia (24%) to carcinoma in situ (50%) (Belinsky et al., 1998). 
Genome-wide analysis of DNA methylation identified increased methylation at 5 to 10% of CpG islands in 
normally unmethylated promoters. Further analysis of the role of methylation in colon cancer cell 
proliferation identified focal gains of DNA methylation at CpG islands in the promoter regions of several 
genes compared to a DNA methyltransferase knockout control (De Carvalho et al., 2012). Ectopic 
expression decreased proliferation of colon cancer cells, suggesting that epigenetic silencing of these 
genes by DNA methylation promotes tumorigenesis in these cells. The dysregulation of histone 
acetylation is also observed in several cancers. Fusion of the histone acetyltransferase MOZ with the 
transcription factor TIF2 is sufficient to transform myeloid progenitor cells and induce acute myeloid 
leukemia in mouse bone marrow transplant models (Deguchi et al., 2003). Furthermore, binding of the 
histone acetyltransferase p300 to the MOZ-TIF2 gene fusion is necessary for transformation, suggesting 
that dysregulation of histone acetylation is plays a role in tumorigenesis.  
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Chapter 3 will review the mechanisms of resistance to targeted therapy, as well as summarize my 
work in collaboration with Zawistowski and Bevill et al., studying the mechanism of epigenetic remodeling 





CHAPTER 3: MECHANISMS OF RESISTANCE TO THERAPY 
Beginning with the FDA approval of imatinib for the treatment of chronic myeloid leukemia in 
2001, kinase inhibitors have been developed for nearly all oncogenic indications with the promise of 
potent, highly selective and non-toxic compounds for the treatment of cancer. Imatinib targets the 
constitutively active BCR-ABL gene fusion of the BCR and ABL kinases caused by a chromosomal 
translocation in leukemia patients. This drug is incredibly effective as a monotherapy, with a ten-year 
survival rate of 80% in CML patients treated with imatinib (Hehlmann et al., 2017). The excitement from 
this success cannot be understated: patients that were previously hospitalized with stable or progressive 
disease started taking a once-daily tablet and were able to get out bed or even exercise (Dreifus, 2009). 
However, in the years since the approval of imatinib, we have come to realize that the success of this 
drug in CML patients is the exception, not the rule. In many cases, patients treated with a kinase inhibitor 
will exhibit a pathological partial response, followed by progression during continued treatment. Kinase 
inhibitor resistance can be classified into three general categories: intrinsic resistance (Figure 3A), 
acquired resistance, and adaptive resistance.  
 
Intrinsic Resistance 
The Cancer Genome Atlas study sequenced over 500 breast cancer tumors and identified over 
30,000 somatic mutations, most of which are believed to be background mutations unrelated to cancer 
progression. Previous studies suggest that initiation of tumor progression requires genomic alterations in 
founding tumor cells (Stratton et al., 2009). Deep sequencing and the development of molecular subtypes 
have improved initial diagnosis, but tumors can carry pre-existing secondary mutations that confer 
resistance to therapy, leading to non-durable response to the drug (Stratton et al., 2009). A study of 
HER2-positive breast cancer in a genetically engineered mouse model revealed that mice with a PIK3CA 
mutation in combination with HER2 amplification demonstrated shorter tumor latencies and were more 





Figure 3. Intrinsic and acquired resistance mechanisms in breast cancer.  (A) HER2-enriched breast cancer cells can harbor 
PIK3CA mutations, which drive intrinsic resistance to targeted HER2 receptor therapy (trastuzumab).  During resistance, mutant 
PIK3CA is able to drive downstream growth signaling through AKT independent of HER2 receptor activity. (B) During acquired 
resistance, tumors harboring mutations such as PIK3CA are selected for over a time course of treatment resulting in an initial tumor 
response followed by outgrowth of resistant PIK3CA mutant cells. Tumor populations can also be pre-enriched for a resistance 






trastuzumab alone and in combination with either lapatinib or pertuzumab. These data suggested that 
mutations in PIK3CA reduce oncogene addiction to HER2 and drive intrinsic resistance to HER2 targeted 
therapies by activating growth signaling independent of the HER2 receptor (Figure 3A). Similarly, FGFR1 
amplification is observed in 16-27% of luminal B breast tumors, and is associated with poor prognosis 
and resistance to hormone therapy. In a panel of luminal breast cancer cell lines, FGFR1 amplification 
results in enhanced ligand-independent signaling, and increased activation of the PI3K and MAPK 
pathways. Furthermore, FGFR1 amplification increased resistance to 4-hydroxytamoxifen, and knock-
down of FGFR1 by siRNA re-sensitized cells to hormone therapy. These data demonstrate that 
amplification of FGFR1 in luminal breast cancer results in increased activation of the PI3K and MAPK 
signaling pathways, and reduces estrogen dependence in luminal breast tumors.  
 
Acquired Resistance 
Several studies following treatment with targeted inhibitors have demonstrated that genomic 
alterations during the course of treatment can increase resistance to therapy. Single molecule sequencing 
of breast tumors demonstrates that point mutations occur at low frequency and accumulate gradually, 
increasing tumor diversity (Wang et al., 2014). A serial sequencing study of circulating tumor DNA from 
breast cancer patients before and after treatment demonstrated that low frequency mutations can be 
enriched during the course of treatment (Murtaza et al., 2013). Deep sequencing of breast cancer 
patients was used to quantify the enrichment of mutations in circulating tumor DNA before and after 
treatment with paclitaxel to identify possible mechanisms of resistance to the drug. Deep sequencing 
demonstrated that mutant PIK3CA in circulating tumor DNA rose from 14% to 34% during the course of 
treatment with paclitaxel. Previous studies have demonstrated that PIK3CA mutations confer resistance 
to paclitaxel, which suggests that drug-resistant cells are enriched during the course of treatment (Isakoff 
et al., 2005). These results demonstrate that low frequency mutations that confer a survival benefit can be 
enriched during the course of treatment, and result in resistance to therapy after an initial therapeutic 
response (Figure 3B). In luminal breast cancer, researchers sequenced the tumors of 11 relapsed 
patients following treatment with hormone therapy to identify mechanisms of resistance to the drug 
(Robinson et al., 2013). Analysis of the sequencing results revealed activating mutations in the ligand-
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binding domain of the ER. These mutations cause activation of the ER independent of ligand, and allow 
tumor proliferation in the presence of the drug. This study suggests that ligand-independent activation of 
the ER induces proliferation of cells harboring the mutation and these cells are selected during treatment 
resulting in increased resistance to hormone therapy in luminal breast cancer. 
 
Adaptive Resistance 
While the incidence of genomic alteration in kinase signaling pathways may suggest several 
kinases are tractable drug targets, the resiliency and plasticity of these signaling networks remains a 
challenge for the durability of kinase inhibitors as single agents (Figure 4A). An in vitro study of luminal 
breast cancer cell lines used RPPA to study kinome activation in response to long-term estrogen 
deprivation to identify mechanisms of resistance to hormone therapy in luminal breast cancer. These 
experiments identified increased activation of mTORC1 and PDK1 in response to hormone deprivation, 
which was abrogated by treatment with the PI3K-mTOR inhibitor BEZ-235 (T. W. Miller et al., 2010).  
Targeted therapies have dramatically increased survival of patients with HER2-enriched breast 
tumors, but recent studies have shown that blocking activation of HER2 by biological or chemical 
inhibitors induces rapid adaptive responses that overcome the action of the drug (Stuhlmiller et al., 2015). 
This adaptation can lead to stable resistance that allows the cells to survive and proliferate in the 
presence of the drug. While there is significant heterogeneity in the response to drug across multiple 
HER2-positive breast cancer cell lines, inhibition of HER2 by the chemical inhibitor lapatinib generally 
leads to FOXO-dependent transcriptional upregulation of multiple RTKs that re-activate the MAPK and 
AKT pathways. Several studies have demonstrated that inhibition of HER2 activity induces expression of 
HER3 and IGF1R, which can be phosphorylated by residual HER2 kinase activity, leading to pathway re-
activation and resistance (Garrett et al., 2011; Huang et al., 2010). Activation of non-receptor tyrosine 
kinases has been observed upon inhibition of HER2-amplfied breast cancer cells with lapatinib, including 
multiple SRC family kinase members (Rexer et al., 2011). The transcriptional upregulation of a 
combination of kinases and the heterogeneity of this response in multiple breast cancer cell lines 





Figure 4: Adaptive resistance mechanisms in breast cancer. (A) (1) Inhibition of target kinase induces (2) loss of negative feedback 
regulation, which results in a transcriptional response with induction of adaptive response genes and RTKs. (3) RTKs are then 








for combination treatments in HER2-positive breast cancer. The high incidence of PIK3CA amplification in 
HER2 breast cancer (39%) suggests that these cancers may be sensitive to therapies targeting the PI3K-
AKT signaling pathway. However, similar to lapatinib studies, treatment with an AKT inhibitor resulted in 
activation of HER3, IGF1R, and INSR in as little as 24 hours following treatment (Chandarlapaty et al., 
2011). These studies highlight the adaptability of HER2-addicted cells to multiple targeted inhibitor 
treatments.  
Triple negative breast cancers in the basal-like and claudin-low molecular subtypes are 
characteristically depleted of ER, PR and HER2 expression, and no molecular targeted therapy is 
currently available for treatment of these molecular subtypes. Aside from PIK3CA mutations, triple 
negative breast cancers are characterized by a limited number of mutations in genes of druggable 
targets. The role of gene amplifications in tumor cell proliferation and survival remains unclear, but genes 
in the PI3K-AKT and MAPK pathways are commonly amplified in basal-like breast cancer, including 
PIK3CA, KRAS, BRAF, and EGFR. Significant amplification of genes in the MAPK pathway suggests that 
targeting this pathway may be an effective molecular therapy for this disease. Treatment of triple negative 
cell lines with the MEK inhibitor selumetinib induced rapid destabilization and degradation of c-Myc, 
resulting in the upregulation and activation of RTKs including PDGFRb, DDR1 and VEGFR2 within as 
little as 24 hours following treatment (Duncan et al., 2012). In each case of adaptive resistance, targeting 
kinases involved in proliferation and survival signaling led to pathway re-activation by the loss of negative 
feedback, and transcriptional upregulation of alternative kinases to promote pathway reactivation or 
bypass signaling in the presence of the drug (Figure 4A). 
 
Subtype Specific Gene Expression in Response to Trametinib in TNBC 
Work published in collaboration with Zawistowski and Bevill et al., demonstrates that triple 
negative breast cancer cell lines can be classified in basal-like or claudin-low molecular subtypes using 
RNA-Seq gene expression analysis. Basal-like breast cancers are enriched in epithelial genes including 
KRT5, KRT17, and ITGB4, whereas claudin-low breast cancers express mesenchymal genes VIM, 
SNAI1, and VEGFA (Perou et al., 2000; Prat et al., 2010). In response to acute trametinib treatment, the 





Figure 5: Unique Adaptive Response to Trametinib Treatment in Triple Negative Breast Cancer Subtypes2. (A) Immunoblot analysis 
of RTK expression in distinct molecular subtypes of breast cancer. (B) Transcriptional response to trametinib treatment in basal-like 
and claudin low cell lines following 24 hr treatment with 500 nM trametinib. (C) GSEA analysis of gene expression in SUM-159 cells 
following acute trametinib treatment. (D) Tyrosine kinases induced greater than 1.5-fold in basal-like (blue) and claudin-low (red) cell 
lines in response to trametinib. (E) Significant kinases (p-value < .05) identified by DESeq analysis of the kinome response in basal-
like and claudin-low breast cancer cell lines. Unique kinases are highlighted in basal (blue) and claudin-low (red), common kinases 
shown in grey. Kinases identified in patient samples indicated with pink asterisk. (F) Flow cytometry analysis of SUM-229PE cells 
following staining with epithelial antigens EpCAM and CD49f. (G) Transcriptional response of EpCAM+ and EpCAM- subpopulations 
following 24 hr treatment with 30 nM trametinib. Venn diagram displays uniquely upregulated genes identified in EpCAM+ (blue) and 
EpCAM- (red). Commonly upregulated genes highlighted in grey. (H) Kinome response to trametinib treatment distributed across all 
kinase families in EpCAM+ (blue) EpCAM- (red) or both (grey). (I) Immunoblot analysis of kinase expression in EpCAM+ and 
EpCAM- isolated subpopulations following 24 hr treatment with 30 nM trametinib.  
                                                   
2 Figure adapted from (Zawistowski et al., 2017) 
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FGFR2, a response which is distinct from the claudin-low cell line SUM-159PT, which upregulates RTKs 
PDGFRb and DDR1 (Figure 5A). RNA sequencing was performed following acute treatment with 
trametinib of three basal like cell lines HCC1806, SUM-149 EpCAM+, and MDA-MB-468, as well as three 
claudin-low cell lines SUM-159PT, HS 578T, and WHIM12. Each of these six cell lines dynamically 
respond to trametinib treatment, with a total transcriptional response ranging from 5.8% of the 
transcriptome in WHIM12, to 35.2% of the transcriptome in SUM-159 cells (Figure 5B). GSEA analysis of 
the transcriptional response in SUM-159 cells reveals the enrichment of MYC targets in the control 
treated sample, indicating that loss of MYC observed in immunblots of SUM-159 cells following trametinib 
treatment (Figure 5A) results in downregulation of MYC target expression. In each of the triple-negative 
breast cancer cell lines we tested, we observed the upregulation of tyrosine kinases in response to 
trametinib treatment. Upregulated tyrosine kinases identified in each cell line basal like (blue) and claudin-
low (red) cell lines are highlighted on the tyrosine kinase branch of the kinome tree (Figure 5D). We 
identified tyrosine kinases that are commonly upregulated in both basal-like and claudin-low breast 
cancer cell lines, highlighted in grey (Figure 5E), which suggests that MYC may bind similar DNA 
sequences or transcriptional factors at these genes and loss of MYC activates target gene transcription. 
However, we also observe the upregulation of tyrosine kinases in response to trametinib treatment that 
are distinct in basal-like (blue) and claudin-low (red) breast cancer cell lines (Figure 5E). This suggests 
that there are unique regulatory elements in basal-like and claudin-low breast cancer that determine the 
transcriptional response to trametinib in these molecular subtypes. The SUM-229PE cell line was isolated 
from the pleural effusion of a triple negative breast cancer patient, which contains epithelial and 
mesenchymal subpopulations that we identified by flow cytometry following staining for the epithelial 
antigens EpCAM and CD49f (Figure 5F). We isolated these two subpopulations by FACS, then treated 
the isolated subpopulations with 30 nM trametinib for 24 hours. These two subpopulations both 
dynamically respond to trametinib treatment, with a total transcriptional response of 15% of the 
transcriptome in the EpCAM+ subpopulation, and 9.1% of the transcriptome in the EpCAM- subpopulation 
(Figure 5G). We identified 280 genes that were commonly upregulated in both subpopulations in 
response to acute trametinib treatment, as well as 594 genes that were uniquely upregulated in the 
EpCAM+ subpopulation, and 369 genes that were uniquely upregulated in the EpCAM- subpopulation. 
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The kinome rapidly adapts to trametinib treatment in both the EpCAM+ and EpCAM- subpopulation, with 
the upregulation of several kinases in both the EpCAM+ and EpCAM- subpopulation (Figure 5H) 
highlighted in grey, as well as several kinases that are uniquely upregulated in the EpCAM+ 
subpopulation (blue) or the EpCAM- subpopulation (red). Immunoblots of both the EpCAM+ and EpCAM- 
subpopulations following trametinib demonstrate that these subpopulations both upregulate the collagen-
activated receptor tyrosine kinase DDR1 (Figure 5I). However, the EpCAM+ subpopulation uniquely 
upregulates FGFR2, an RTK upregulated in several basal-like cell lines, whereas the EpCAM- 
subpopulation uniquely upregulated PDGFRb, an RTK upregulated in several claudin-low cell lines. 
 
Transcriptional Response to Trametinib is Associated with Epigenetic Remodeling 
Even though they were isolated from the same patient, the unique responses in the EpCAM+ and 
EpCAM- subpopulation suggest that differences in epigenetic imprinting may determine response to 
trametinib. Therefore, we performed a survey of epigenetic marks of transcriptional activation in SUM-159 
cells to determine if epigenetic remodeling in response to trametinib regulates the transcriptional 
response to drug. DDR1 expression has been shown to be transcriptionally responsive in both basal-like 
and claudin-low breast cancer cell lines, so we examined the DDR1 locus in SUM-159PT cells to define 
the role of epigenetic remodeling on target gene transcription at this site. We observed the enrichment of 
H3K4me3 at the transcription start site of DDR1, which has been shown in previous studies to delineate 
the promoter region of actively transcribed genes (Figure 6A, navy) (Guenther et al., 2007). Furthermore, 
we identified an enhancer region enriched in H3K4me1 approximately 20 kb from the promoter region 
(Figure 6A, yellow). Following 24 hr treatment of SUM-159PT cells with 100 trametinib, histone 
acetyltransferase p300 binding is enriched at promoter and enhancer regions in the trametinib treated 
sample relative to the DMSO control (Figure 6, cyan). Furthermore, we observed increased H3K27ac 
(Figure 6A, green) in trametinib treated samples at p300 binding sites, likely the result of increased 
binding and histone acetylation by p300. Furthermore, we identified increased binding of the 
transcriptional co-activator BRD4 at sites of increased H3K27ac (A. Dey et al., 2003; Jang et al., 2005). In 





Figure 6. Transcriptional Response to Trametinib is Associated with Chromatin Remodeling in TNBC3. (A) ChIP-Seq at DDR1 locus 
for BRD4 (light blue), H3K27ac (green), Mediator (pink), p300 (cyan), H3K4me1 (yellow), H3K4me3 (navy) in SUM-159 cells 
following treatment with DMSO (-) or 100 nM trametinib for 24 hours (+). (B) Density of BRD4, H3K27ac, MED1, and p300 peaks at 
50 highest ranking BRD4 peaks following 24 hr treatment with DMSO, 100 nM trametinib, 300 nM JQ1, or combination of JQ1 and 
trametinib. Quantification of BRD4 density at enhancer peaks following 24 hr treatment with DMSO, trametinib, JQ1 or the 
combination in SUM-159PT (C) or HCC1806 (D). (E) Quantification of enhancers in EpCAM+ (blue) and EpCAM- (grey) 
subpopulations by BRD4 density following 24 hr treatment with DMSO (dotted line) or 30 nM trametinib (solid line). (F) Fold-change 
of BRD4 peak density relative to the transcription of target gene +/- 200 kb from peak following 24 hr treatment with 100 nM 
trametinib compared to DMSO control. (G) Classification of BRD4 peak location in SUM-159PT and HCC1806 for peaks that are 
induced greater than two-fold with trametinib treatment and suppressed greater than two-fold with JQ1 in combination, induced 
greater than two-fold with trametinib treatment and suppressed greater than two-fold with JQ1 in combination, or lost with trametinib 
treatment.  (H) Transcriptional response of indicated kinases associated with BRD4 peaks greater than two-fold with trametinib 
treatment and suppressed greater than two-fold with JQ1 in combination. 
                                                   
3 Figure adapted from (Zawistowski et al., 2017) 
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largest enhancer peaks (Figure 6B, blue), relative to the DMSO control (Figure 6B, grey). Accordingly, we 
identified increased H3K27ac and BRD4 binding concomitant with increased p300 binding at these 
enhancer peaks following trametinib treatment (Figure 6B, blue) relative to control (Figure 6B, grey). 
However, increased BRD4 binding in response to trametinib is abrogated when the BRD4 inhibitor JQ1 is 
added in combination with trametinib (Figure 6B, black). We defined enhancer peaks genome wide by 
BRD4 peaks within 200 kb 5’ of the TSS or 200 kb 3’ of the TES, but outside the promoter region +/- 5 kb 
from the TSS. We observed robust remodeling of the enhancer landscape in response to trametinib 
treatment, which induced the formation of de novo enhancer regions enriched in BRD4 binding. We 
identified 1445 BRD4-enriched enhancers in SUM-159 cells following treatment with the DMSO control, 
which increases to 2782 enhancers following treatment with trametinib (Figure 6C). Furthermore, ranking 
enhancers by BRD4 density allowed us to identify super enhancers (Lovén et al., 2013; Parker et al., 
2013; Whyte et al., 2013), which increased from 60 super enhancers in the DMSO control to 162 super 
enhancers in trametinib treated sample. Similar to the effect we observed at the largest BRD4 peaks in 
Figure 6B, we observed decommissioning of both enhancers and super enhancers when JQ1 was 
combined with trametinib treatment. We identified 22 super enhancers in samples treated with both JQ1 
and trametinib, compared to the 60 super enhancers we identified in the DMSO control and the 162 super 
enhancers we identified following treatment with trametinib alone. Epigenetic remodeling in response to 
trametinib treatment was also observed in the basal-like breast cancer cell line HCC1806, which created 
de novo enhancers following treatment, and were abrogated in combination with JQ1. The formation of de 
novo enhancers was identified in the EpCAM+ and EpCAM- subpopulations as well, which suggests that 
the recruitment of BRD4 to enhancer regions in response to trametinib treatment may be a general 
mechanism to stimulate growth in TNBC in response to the loss of MAPK pathway activation. Therefore, 
we examined the correlation between the recruitment of BRD4 to enhancer regions, and the transcription 
of the gene most proximal to the peak. Increased gene expression was positively correlated with 
increased BRD4 recruitment, suggesting that BRD4 binding may increase transcription activation of target 
genes (Figure 6F). However, we also observed increased binding of BRD4 at genes that were 
downregulated in response to trametinib treatment, which indicates that these BRD4 enriched enhancers 
may not be regulating the expression of the most proximal gene, or may play a role in the repression of 
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transcription. We hypothesized that epigenetic remodeling of BRD4 peaks in promoter or enhancer 
regions may have differential effects on transcriptional response, so we classified BRD4 peaks by 
distance relative to the TSS. BRD4 peaks were classified as a 5’ enhancer peak if it was located between 
-200 kb to -5 kb relative to the TSS, a 3’ enhancer peak if it was located 0 to 200 kb from the TES, a 
promoter peak if it was located +/- 5 kb from the TSS, a gene body peak if it was located in gene exons or 
introns, or an orphan peak if no classification applied. This scheme was used to classify peaks with the 
following response patterns: induced by trametinib and suppressed by the addition of JQ1, induced by 
trametinib but not suppressed by the addition of JQ1, or suppressed by trametinib alone (Figure 6G). In 
each of the three classes, BRD4 peaks were most commonly found in the 5’ enhancer region, and this 
class accounts for approximately half of all BRD4 peaks induced in response to trametinib treatment in 
SUM-159 and HCC1806 cells. Interestingly, BRD4 peaks located in the promoter region of genes were 
strongly induced in response to trametinib treatment, but these peaks seemed to be more resistant to 
inhibition by JQ1, which suggests that bromodomain activity is required for binding at enhancers but not 
promoter regions. BRD4 peaks suppressed in response to trametinib represents approximately 25% of 
the total number of gained peaks, indicating that loss of BRD4 binding at these sites may facilitate BRD4 
recruitment at enriched peaks. Previous studies demonstrate that decommissioning of BRD4 enhancer 
peaks allows rapid chromatin remodeling to finely tune the activation of target genes (J. D. Brown et al., 
2014). Examination of BRD4 peaks associated with kinases activated in response to trametinib treatment 
in the claudin-low SUM-159 cell line and the basal-like HCC1806 cell line revealed that BRD4 binding 
increases in all peak classes, further suggesting that BRD4 contributes to the upregulation of target 
kinases (Figure 6H). These results indicate that genome-wide epigenetic remodeling of BRD4 density 
may regulate transcription of target kinases to reactivate growth signaling in the presence of trametinib. 
 
Transcriptional Activation in Response to Trametinib by Distal Enhancers 
 We hypothesized that BRD4 recruitment to enhancer regions associated with kinases increased 
target kinase expression in response to trametinib treatment. Therefore, we assessed BRD4 recruitment 




Figure 7. Regulation of Target Gene Expression by Distal Enhancers4. (A) ChIP-Seq for BRD4 binding at DDR1 enhancer region 
during treatment with 100 nM trametinib. Enrichment can be observed by 1 hour of treatment (green), and reaches maximal levels at 
24 hours (orange). (B) Analysis of genome-wide BRD4 ChIP-Seq demonstrates that recruitment to enhancers and super enhancers 
genome wide observed by 1 hour of treatment (green), but reaches maximal levels by 72 hours (pink). (C) Immunoblot for DDR1 
and MYC during trametinib treatment demonstrates DDR1 increases concomitant with MYC loss. (D) ChIP-Seq for BRD4 reveals 
BRD4 recruitment at enhancer regions associated with the regulatory subunit of PI3K, PIK3R1, as well as the receptor tyrosine 
kinase KDR. (E) Two independent CRISPR sgRNAs were designed to knock out the enhancer associated DDR1. Immunoblot for 
DDR1 following treatment with trametinib demonstrates enhancer knock out abrogates DDR1 expression compared to sgRNA 
control. 
  
                                                   
4 Figure adapted from (Zawistowski et al., 2017) 
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with 100 nM trametinib (Figure 7A) for 0 hr (blue), 1 hr (green), 4 hrs (olive), 24 hrs (orange), and 72 hrs 
(pink). BRD4 is recruited to the DDR1 enhancer region in as little as 1 hour of treatment with 100 nM 
trametinib, and continues to increase to a maximal level at 24 hours. While BRD4 enrichment continues 
to persist at 72 hours of trametinib treatment, BRD4 recruitment is slightly diminished relative to the 
enrichment at 24 hours. Genome-wide recruitment of BRD4 to enhancers is observed after 1 hour of 
treatment with trametinib, but the total number of enhancer and superenhancer peaks continues to 
increase up to 72 hours of trametinib treatment. Furthermore, immunoblot analysis of DDR1 expression 
demonstrates that DDR1 levels increase concomitant with increased recruitment of BRD4 (Figure 7A). 
Increased expression of DDR1 was observable as early as 1 hour of trametinib treatment and maximal 
expression was reached by 24 hours (Figure 7C). We examined other superenhancers associated with 
kinases that were upregulated in response to trametinib, and identified the enrichment of BRD4 at the 
enhancer region near PIK3R1, a regulatory subunit of PI3K, as well at the enhancer region near KDR 
(Figure 7D, blue). Furthermore, addition of the BRD4 inhibitor JQ1 in combination with trametinib 
abolished the recruitment of BRD4 at these enhancer regions (Figure 7D, black), suggesting that the 
addition of JQ1 is sufficient to block epigenetic remodeling and kinome reactivation in response to 
treatment. We hypothesized that the recruitment of BRD4 at the enhancer region of DDR1 activates 
expression of DDR, so we designed CRISPR sgRNA guides to knock out the DDR1 enhancer region and 
quantify DDR1 expression in the presence of trametinib without the enhancer. Following treatment with 
100 nM trametinib, homozygous knockout of the DDR1 enhancer significantly decreases expression of 
DDR1 relative to the non-targeting sgRNA control. These data indicate that the enhancer region of DDR1 
activates transcription of DDR1, suggesting that epigenetic remodeling of this enhancer in response to 
trametinib is sufficient to activate transcription of receptor tyrosine kinases to reactivate MAPK. 
 Gene expression analysis of triple negative breast cancer cell lines demonstrates that the basal-
like molecular subtype is characterized by the baseline expression of epithelial genes, whereas the 
claudin-low molecular subtype is characterized by the baseline expression of mesenchymal genes. The 
phenotypic differences between these two molecular subtypes is further evident in the differential 
response to treatment with trametinib, which induces a transcriptional response that is unique to each 
molecular subtype. DESeq analysis of kinase transcription demonstrates that MAP2K6, FRK, and MYLK 
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are significantly transcriptionally activated in basal-like breast cancer cell lines in response to trametinib 
relative to claudin-low cell lines. Furthermore, this analysis identified DCLK1, IP6K3 and NPR1 are 
significantly transcriptionally activated in claudin-low cell lines in response to trametinib relative to basal-
like cell lines. However, many kinases are commonly upregulated in both molecular subtypes, including 
DDR1 and JAK1, which suggests that there is a global epigenetic response to MEK inhibition to stimulate 
pathway reactivation. Zawistowski and Bevill et al. demonstrate that epigenetic remodeling occurs in as 
little as 1 hour in response to trametinib treatment, and BRD4 is recruited to the 5’ enhancer regions 
associated with transcriptionally activated kinases. Pathway reactivation by transcriptional upregulation 
has been observed in several other preclinical models in response to targeted therapy. Stratikopoulous 
and colleagues demonstrated that treatment of metastatic breast cancer with the PI3K inhibitor GDC-
0941 induces the expression of INSR, IGF1R, HER2 and HER3, which can be blocked by combining JQ1 
(Stratikopoulos et al., 2015). A similar response was observed in HER2-positive breast cancer cell lines 
following treatment with the ERBB family kinase inhibitor, lapatinib. Treatment of HER2-positive breast 
cancer cell lines induced epigenetic remodeling and transcriptional activation of HER3, IGF1R, DDR1, 
MET and FGF family RTKs, which was blocked with JQ1 in combination with lapatinib (Stuhlmiller et al., 
2015). These results indicate that epigenetic remodeling in response to targeted therapy is sufficient to 
upregulate expression of RTK and increase pathway activation in the presence of drug. However, the 





CHAPTER 4: DETERMINANTS OF TRAMETINIB RESPONSE IN TNBC 
Intratumor heterogeneity arising from genetic mutation and epigenetic remodeling represents a 
significant challenge to therapeutic durability and prevention of resistance. Deep sequencing of tumors 
has revealed that most mutations identified in the tumor mass could not be detected in all tumor regions 
(Gerlinger et al., 2012). This heterogeneity increases the likelihood that drug tolerant clones will persist 
throughout treatment and lead to relapse. Indeed, whole exome sequencing of circulating tumor DNA 
isolated from breast cancer patients during treatment revealed the enrichment of low frequency mutations 
that mediate therapeutic resistance (Murtaza et al., 2013). However, several studies have also observed 
a spectrum of phenotypes can emerge from tumor cells with similar genotypes (Chaidos et al., 2013; 
Wang et al., 2014). Therefore, many hypothesize that the epigenetic plasticity of cancer also contributes 
to the persistence of drug resistant cells (R. Brown et al., 2014; Dean et al., 2005; Easwaran et al., 2014). 
A recent study of circulating tumor cells revealed that these cells are not always committed to a single cell 
state, but can display a mixture of phenotypes (Yu et al., 2013). This study also showed that epithelial 
and mesenchymal subpopulations of circulating tumor cells were differentially sensitive to treatment with 
PI3K and MEK inhibitor. Recent work interrogating resistance to targeted therapy demonstrated that 
breast cancer cells can become drug tolerant by switching cell state (Risom et al., 2018). While tolerance 
can emerge from global remodeling that induces cell state switching, it can also be caused by the 
epigenetic activation of specific genes to stimulate resistance (Sharma et al., 2010). These results 
suggest that genetic heterogeneity and epigenetic plasticity play essential roles in mediating drug 
resistance and selection of drug tolerant phenotypes. 
Triple negative breast cancer (TNBC) is a heterogenous disease clinically characterized by the 
absence of the estrogen, progesterone and HER2 receptors. Unlike other breast cancer subtypes, there 
are no FDA-approved targeted therapies currently available for triple negative breast cancer patients. 
These patients are treated with a combination of surgery, radiation therapy, and chemotherapy (Wahba 
and El-Hadaad, 2015). Clinical studies demonstrate that while triple-negative breast cancer patients have 
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the best pathological complete response rates of any breast cancer subtype, TNBC patients with residual 
disease have the worst survival (Liedtke et al., 2008). Deep sequencing of TNBC patients revealed a 
broad distribution in the number of clonal subpopulations within individual tumors, suggesting that the 
genetic heterogeneity contributes to outcome (Shah et al., 2012). These results indicate that 
heterogeneity in TNBC breast cancer represents a significant obstacle to improvement of patient 
outcomes with current therapies. Therefore, identifying durable targeted therapies for triple-negative 
patients is essential to improving outcomes for patients with heterogeneous tumors. 
Despite their initial promise, kinase inhibitors have often been ineffective as a monotherapy due 
to epigenetic remodeling and transcriptional activation that occurs in response to treatment. The Cancer 
Genome Atlas Project sequenced 510 breast cancer tumors, which identified the overexpression of 
EGFR, KRAS, and BRAF (Cancer Genome Atlas Network, 2012). As a result, there are ongoing clinical 
trials examining the safety and efficacy of the inhibitors of the MAPK signaling pathway in breast cancer 
patients, including MEK inhibitors selumetinib and trametinib. A window-of-opportunity trial enrolling triple-
negative breast cancer patients treated with trametinib demonstrated that patients treated with trametinib 
for seven days rapidly respond to treatment, increasing expression of receptor tyrosine kinases (RTKs) to 
reactivate MAP kinase signaling (Zawistowski et al., 2017). Similar work examined the adaptive response 
to AKT inhibition, which revealed the upregulation of receptor tyrosine kinases in several preclinical 
models (Chandarlapaty et al., 2011). An analogous observation was made following treatment of HER2-
positive breast cancer with the ERBB-family kinase inhibitor lapatinib, but combining a BET bromodomain 
inhibitor with lapatinib abrogated transcriptional activation and produced a synergistic effect (Stuhlmiller et 
al., 2015). ChIP-Seq experiments in triple negative breast cancer demonstrated that treatment with 
targeted therapy increases acetylation histone H3 at lysine 27 (H3K27ac) concomitant with the 
recruitment of the histone acetyltransferase p300 and increases binding of the BET bromodomain protein 
BRD4 (Zawistowski et al., 2017). These results suggest that epigenetic remodeling by increased 
H3K27ac and BRD4 recruitment play an essential role in transcriptional activation in response to targeted 
therapy.  
We aim to understand the regulatory elements that control epigenetic remodeling in response to 
targeted therapy in heterogenous breast cancers by studying the response in epithelial and mesenchymal 
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subpopulations of the heterogeneous TNBC cell line SUM-229PE. These cells were isolated from the 
pleural effusion of a breast cancer patient following treatment with chemotherapy, and express 
cytokeratins consistent with their origin from luminal breast epithelial cells (Forozan et al., 1999). A 
comprehensive analysis of heterogeneity in breast cancer cell lines identified two distinct subpopulations 
with unique morphologies that differentially express epithelial markers (Keller et al., 2010). Furthermore, 
an siRNA screen in the epithelial and mesenchymal subpopulations of SUM-229 cells discovered that 
SMARCD3, a regulatory subunit of the SWI/SNF chromatin remodeling complex, is necessary for the 
maintenance of phenotype, suggesting the phenotype is epigenetically controlled (Jordan et al., 2013). 
This work aims to understand how these distinct epithelial and mesenchymal subpopulations 
epigenetically control normal gene expression and dictate the response to therapy, to provide insight into 
how resistance may emerge during treatment with targeted therapy. 
 
Subpopulations in TNBC Have Similar Genotypes with Distinct Phenotypes 
The cell line SUM-229PE was isolated from the pleural effusion of a triple negative breast cancer 
patient, and contains cells with epithelial and mesenchymal morphologies. Immunostaining of SUM-
229PE cells (Figure 8A) reveals a subpopulation of cells with an elongated phenotype, prominent 
filamentous actin fibers (green) and perinuclear vimentin (red), as well as a subpopulation of cells with a 
rounded phenotype that stain for elevated levels of the epithelial marker EpCAM (blue). The SUM-229PE 
cell line was analyzed by flow cytometry (Figure 8B) following staining for epithelial cell surface markers 
EpCAM and CD49f (integrin a6). We observed a subpopulation of cells that stained positive for EpCAM 
and CD49f (POS) and a subpopulation of cells that stained negative for EpCAM and CD49f (NEG). The 
POS and NEG subpopulations were isolated by FACS to greater than 99.9% purity, then cultured for up 
to six weeks after isolation. Following six weeks of culture after isolation, less than 1% of the NEG 
subpopulation staining positive for EpCAM and CD49f. We previously reported that whole exome 





Figure 8. Genetically Similar Subpopulations in TNBC Express Distinct Phenotypes. (A) Immunofluorescence staining of SUM-229 
parental culture for EpCAM (blue), Actin (green), and Vimentin (red). (B) Flow cytometry of SUM-229 parental culture containing an 
epithelial subpopulation (POS) that stains positive for epithelial antigens EpCAM and CD49f, and a mesenchymal subpopulation 
(NEG) the stains negative for EpCAM and CD49f. POS and NEG subpopulations were isolated by FACS, and analyzed after 42 
days of continuous culture. (C) Comparison of total reads containing non-synonymous mutations that were identified by whole 
exome sequencing of POS (x) and NEG (y) subpopulations. (D) Comparative analysis of gene expression in the isolated 
subpopulations identified 1865 genes that have greater than two-fold expression in the NEG subpopulation compared to the POS 
subpopulation, with a p-value less than 0.05. Similarly,1666 genes have greater than two-fold expression in the POS compared to 
the NEG, with a p-value less than 0.05. (E) DESeq analysis of gene expression in POS and NEG calculates significance of 
differential expression. Dashed lines indicate log2 fold change greater than 1, which is highlighted in POS (blue) and NEG (red). (F) 
Gene ontology analysis of the molecular function of differentially expressed genes identified by DESeq in NEG (red) and POS (blue) 
using the Molecular Function GO terms in the Enrichr database. Combined score calculated using Enrichr database; log of p-value 





subpopulation compared to the reference genome, with no SNVs unique to either subpopulation 
(Zawistowski et al., 2017). We reanalyzed the whole-exome sequencing data using a germline rather than 
somatic mutation caller, and compared the total reads of all variants identified in POS and NEG cells 
(Figure 8C). The germline variant caller identified 133 mutated genes that were unique to either POS or 
NEG subpopulations (Table 2). Furthermore, we performed karyotyping of the POS and NEG 
subpopulations, which revealed that the two subpopulations share similar ploidy and many of the same 
chromosomal aberrations, but the NEG subpopulation contains a higher frequency of dicentric 
chromosomes (Figure 9, Table 3). Despite the genomic similarity of the two subpopulations, we 
hypothesized that the distinct phenotypes we observed in immunofluorescence and flow cytometry 
assays were the result of distinct transcriptional programs in POS and NEG cells. Therefore, we 
performed RNA-Seq on POS and NEG cells to identify the determinants of these differential phenotypes. 
We captured 12744 genes with a minimum of 25 reads in either subpopulation, and classified 29% of the 
transcriptome as differentially expressed between subpopulations, with a minimum two-fold difference in 
expression and a p-value of less than 0.05 (Figure 8D and 8E). To further study these genes, we 
interrogated the molecular function of the 1882 genes differentially expressed in the NEG subpopulation, 
and the 1709 POS differentially expressed in the POS subpopulation using the Enrichr gene ontology 
database (Chen et al., 2013; Kuleshov et al., 2016). Genes specifically expressed in the NEG 
subpopulation are significantly enriched for GO terms associated with a mesenchymal phenotype, 
including PDGF receptor binding, collagen binding, and TGFb receptor binding (Figure 8F). Examination 
of the genes underlying the enrichment of GO terms revealed increased expression of PDGFRA, 
PDGFRB, TGFBR3, TGFB1, FN1, and ITGA11 (Figure 9C-F). Genes specifically expressed in the POS 
subpopulation are significantly enriched for GO terms associated with an epithelial phenotype, including 
cadherin binding and cell-cell adhesion. The genes identified in the POS enriched GO terms showed 
increased expression of CDH1, EPCAM, DSG2, and KRT18 in the POS subpopulation (Figure 9G-I). To 
further define the phenotypes of the POS and NEG subpopulations, we used two genesets from the 
MSigDB developed by Charafe-Jauffret et al., which distinguishes mesenchymal and basal-epithelial 
subtypes using RNA-Seq data collected from 31 different breast cancer cell lines (Charafe-Jauffret et al., 





Figure 9: Supplemental Figure : Genetically Similar Subpopulations in TNBC Express Distinct Phenotypes. (A) Circos plot of single 
nucleotide variants identified in POS and NEG subpopulations relative to reference genome hg19. Heatmap displays allelic 
frequency of variant calls (outer band). Variant mismatch identified with blue mark (inner ring). (B) Cytogenic analysis of POS and 
NEG subpopulations, high frequency of dicentric chromosomes observed in NEG chromosomes (arrows). Cytogenetic abnormalities 
listed in Table 3. (C) Differential gene expression of genes identified in NEG subpopulation by TGFbII Receptor GO term. Values 
represent the log2 transformation of ( POS / NEG ) average gene expression for three replicate RNA-Seq experiments. (D) 
Differential gene expression of genes identified in NEG subpopulation by PDGF Binding GO term. (E) Differential gene expression 
of genes identified in NEG subpopulation by PDGFR Binding GO term. (F) Differential gene expression of genes identified in NEG 
subpopulation by Collagen Binding GO term. (G) Differential gene expression of genes identified in POS subpopulation by 
Heterotypic Cell-Cell Adhesion GO term. (H) Differential gene expression of genes identified in POS subpopulation by Cell-Cell 
Adhesion GO term. (I) Differential gene expression of genes identified in POS subpopulation by Cadherin Binding GO term. (J) 
Heatmap of gene expression of genes in Mesenchymal and Basal genesets developed by Charafe-Jauffret et al. and submitted to 
MSigDB. Heatmap displays log2 transformed, mean-centered, normalized gene expression of triplicate RNA-Seq values in NEG 





Table 2. Gene Expression of Differentially Mutated Genes Identified by Whole Exome Sequencing. Analysis of whole exome 
sequencing of POS and NEG subpopulations using the FreeBayes variant caller identified 133 genes with differential genotypes and 
confidence score greater than Q30. Genes listed with the mean expression of biological triplicate RNA-Seq of NEG and POS 







Table 3. Chromosomal Aberrations Identified by Karyotyping of NEG and POS Subpopulations. Cytogenic analysis was performed 
on twenty G-banded metaphase spreads. “+” indicates the detection of additional copy of the corresponding chromosome, 
“derivative” indicates a chromosomal fragment was identified. “add” or “del” indicates that a chromosomal arm of unusual length was 
detected. Chromosomal arm is indicated with “p” or “q” where applicable. The “iso” notation indicates that an isochromosome was 
identified.   
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triplicate of POS (blue) and NEG (red) RNA-Seq shows distinct enrichment of the genes in the 
mesenchymal geneset in the NEG subpopulation (red), and enrichment of the basal geneset in the POS 
subpopulation (blue). These data demonstrate that despite their genomic similarities, the differentially 
expressed genes in the POS and NEG subpopulations determine the epithelial and mesenchymal 
phenotypes observed in the mixed population. 
 
Epithelial and Mesenchymal Phenotypes are Epigenetically Imprinted 
The genomic similarities in the POS and NEG subpopulations led us to hypothesize that the 
differentially expressed genes were epigenetically imprinted. Therefore, we performed ChIP-Seq for 
transcriptional activation marks histone H3 lysine 27 acetylation (H3K27ac) and bromodomain-containing 
protein 4 (BRD4) binding in POS and NEG subpopulations. We used MACS to identify 16608 H3K27ac 
peaks with a minimum of 5 reads in either the POS or NEG subpopulations, with 4388 peaks (26%) 
greater than two-fold enriched in the POS subpopulation and 5959 peaks (36%) greater than two-fold 
enriched in the NEG subpopulation. Using MACS, these peaks were classified by the type of regulatory 
element and annotated to nearby genes. This comparison revealed enrichment of H3K27ac density at 
peaks near the TWIST1 and ZEB1 loci (red) in the NEG subpopulation relative to the POS subpopulation 
(Figure 10A). TWIST1 and ZEB1 are transcription factors specifically expressed in mesenchymal cells 
that have been shown to be essential regulators of the mesenchymal phenotype (Polyak and Weinberg, 
2009). Furthermore, we identified enrichment of H3K27ac density at peaks near the epithelial-specific 
transcription factors TP63 and ELF3 loci (blue) (Blick et al., 2008; Eckel et al., 2003). Examination of the 
TWIST1 locus (Figure 10C) demonstrates specific enrichment of H3K27ac density in the NEG 
subpopulation (red) surrounding the TWIST1 transcription start site (TSS), compared to the POS 
subpopulation (blue). When comparing the POS and NEG subpopulations at the ELF3 locus (Figure 
10C), however, the opposite is true: we observe specific enrichment of H3K27ac density in the POS 
subpopulation (blue) at the TSS of ELF3 relative to the NEG subpopulation (red). These results suggest 
that epigenetic regulators of transcriptional activation are specifically localized at the TSS of transcription 
factors that help determine phenotype. We further investigated the epigenetic regulation of transcriptional 





Figure 10. Epigenetic Imprinting in Epithelial and Mesenchymal Subpopulations. (A) Comparison of peaks identified and quantified 
by MACS analysis of H3K27ac ChIP-Seq of POS (x) and NEG (y). Peaks associated with epithelial-specific genes are labeled in 
blue, peaks associated with mesenchymal-specific genes are labeled in red. (B) Comparison of peaks identified and quantified by 
MACS analysis of BRD4 ChIP-Seq of POS (x) and NEG (y). Peaks associated with epithelial-specific genes are labeled in blue, 
peaks associated with mesenchymal-specific genes are labeled in red. (C) Sashimi plot of H3K27ac ChIP-Seq density at the 
TWIST1 and ELF3 loci in POS (blue) and NEG (red). (D) Sashimi plot of BRD4 ChIP-Seq density at the TWIST1 and ELF3 loci in 
POS (blue) and NEG (red). (E) Log2-transformed, normalized mean RNA-Seq reads of TWIST1 and ZEB1 in NEG (red) and POS 




subpopulations by ChIP-Seq. We used MACS to identify 12218 BRD4 peaks with a minimum of 2 reads 
in either the POS or NEG subpopulation, with 4169 peaks (34%) greater than two-fold enriched in the 
POS subpopulation, and 2200 peaks (18%) greater than two-fold enriched in the NEG subpopulation. We 
identified increased BRD4 density associated with TWIST1 and ZEB1 in the NEG subpopulation 
compared to the POS subpopulation, and observed similar enrichment of BRD4 density in the POS 
subpopulation associated with ELF3 and TP63 compared to the NEG subpopulation (Figure 10B). 
Focusing in further on BRD4 density at the TSS of phenotype-specific transcription factors (Figure 10D), 
we observe increased BRD4 density at the TSS of TWIST1 in the NEG subpopulation (red) compared to 
the POS subpopulation (blue), and similar enrichment of BRD4 density at the TSS of ELF3 in the POS 
subpopulation (blue) compared to the NEG subpopulation (red). Analysis of gene expression of the 
mesenchymal transcription factors TWIST1 and ZEB1 by RNA-Seq reveals significantly increased 
expression in the NEG subpopulation compared to the POS subpopulation (Figure 10E). Conversely, 
analysis of gene expression of the epithelial transcription factors TP63 and ELF3 by RNA-Seq 
demonstrates elevated expression of TP63 and ELF3 in the POS subpopulation compared to the NEG 
subpopulation (Figure 10F). These results suggest that epigenetic transcriptional activators H3K27ac and 
BRD4 contribute to the subpopulation-specific restriction of transcription factors that define phenotype. 
 
Drug Response Determined by Differential Remodeling of Epigenetic Landscape 
 Previous studies have demonstrated that in response to the MEK inhibitor trametinib, breast 
cancer cells rapidly remodel their epigenetic landscape to induce a transcriptional adaptation that 
reactivates growth signaling of the MAPK pathway (Zawistowski et al., 2017). Therefore, to study the 
epigenetic factors that determine the response to an acute treatment with trametinib, we treated POS and 
NEG subpopulations with 30 nM trametinib for 24 hours. This dose was chosen because it is 
approximately ten-fold higher than the previously published IC50 for these cells, and has been shown to 
be clinically achievable in patients (Infante et al., 2012). Following the acute treatment of trametinib, POS 
and NEG cells were fixed and stained with propidium iodide and analyzed by flow cytometry to quantify 





Figure 11. Differential Transcriptional and Epigenetic Response to Acute Trametinib Treatment in Epithelial and Mesenchymal 
Cells. (A) Cell cycle analysis of POS (blue) and NEG (red) cells following acute treatment with 30 nM trametinib for 24 hours 
compared to DMSO control (grey). (B) Comparison of transcriptional response in POS (x) and NEG (y) to acute treatment with 30 
nM trametinib for 24 hours compared to DMSO control. Genes uniquely upregulated in NEG are highlighted by the red region, 
genes uniquely upregulated in POS are highlighted by the blue region, overlap highlighted by the purple region. (C) Venn diagram of 
genes that are greater than two-fold upregulated following treatment with 30 nM trametinib treatment for 24 hours of POS and NEG. 
In NEG cells, 901 total genes are upregulated, 568 of which are unique. In POS cells, 1234 total genes are upregulated, 901 of 
which are unique. 333 genes are upregulated in both POS and NEG. (D) Gene ontology analysis of genes transcriptionally 
upregulated in POS cells using the Molecular Function GO terms in the Enrichr database. Combined score calculated using Enrichr 
database; log of p-value multiplied by z-score deviation from expected rank. (E) Gene ontology analysis of genes transcriptionally 
upregulated in NEG cells using the Molecular Function GO terms in the Enrichr database. Combined score calculated using Enrichr 
database; log of p-value multiplied by z-score deviation from expected rank. (F) Peaks identified by MACS analysis of H3K27ac 
ChIP-Seq of POS following treatment with 30 nM trametinib for 24 hrs (y) compared to DMSO control (x). Points > y=x+1 (solid line) 
are upregulated greater than two-fold in response to trametinib. Points < y=(x-1) (solid line) are downregulated greater than two-fold 
in response to trametinib. (cont. on pg. 39)  
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(Figure 12A, light blue) increasing G1 occupancy from 30% to 87%, whereas the effect is more modest in 
the NEG cells, (Figure 12A, pink) increasing G1 occupancy from 41% to 67%. To study the response of 
the POS and NEG cells to acute trametinib treatment, we exposed biological replicates of the isolated 
subpopulations to acute trametinib treatment, and analyzed transcription by RNA-Seq. We hypothesized 
that the two subpopulations would exhibit both a unique transcriptional response to trametinib and a 
common response to the drug, so we quantified the log2 fold-change in transcription following trametinib 
treatment relative to the DMSO control in the NEG subpopulation, and compared this response to the 
drug response in the POS subpopulation (Figure 11B). Genes upregulated only in the NEG subpopulation 
are highlighted by the red region, and genes upregulated only in the POS subpopulation are highlighted 
by the blue region. Genes upregulated in both the POS and NEG subpopulations are highlighted by 
overlap of the red and blue regions. We quantified the total genes in each region, represented by the 
venn diagram in Figure 11C. Interestingly, we observed the upregulation of 1234 total genes in the POS 
subpopulation compared to 901 total genes in the NEG subpopulation, concomitant with the stronger 
growth arrest in the POS subpopulation. To determine the role of upregulated genes in the drug 
response, we analyzed the molecular function of genes upregulated in the POS and NEG subpopulations 
in response to trametinib using the Enrichr gene ontology database (Chen et al., 2013; Kuleshov et al., 
2016). In response to acute trametinib treatment, GO analysis identified the enrichment of calcium ion 
binding, PIP3 binding, actin binding and protein tyrosine kinase activity in the POS subpopulation (Figure 
11D)5. Examining the underlying genes, we observe enrichment of several genes regulating the formation 
and binding of F-actin, such as POF1B, SYNPO2, RCSD1 and NEXN, as well as several genes 
controlling phospholipase activity and downstream calcium signaling, such as PLCD1, HIP1R, SYT1, and  
  
                                                   
5 Figure 11. (cont.) (G) Motifs enriched at the summits of H3K27ac peaks upregulated in POS greater than two-fold and found in 
the promoter or enhancer region of genes transcriptionally upregulated two-fold in response to trametinib. (H) Volcano plot of 
transcriptional response of POS cells to acute trametinib treatment. Log2 fold change in gene expression in trametinib treated 
sample relative to DMSO control. Genes upregulated greater than two-fold highlighted in blue. Significance estimated by analysis of 
biological triplicate RNA-Seq reads using DESeq2. Transcription factors identified in Fig. 3G highlighted in yellow. (I) Peaks 
identified by MACS analysis of H3K27ac ChIP-Seq of NEG following treatment with 30 nM trametinib for 24 hrs (y) compared to 
DMSO control (x). Points > y=x+1 (solid line) are upregulated greater than two-fold in response to trametinib. Points < y=(x-1) (solid 
line) are downregulated greater than two-fold in response to trametinib. (J) Motifs enriched at summits of H3K27ac peaks 
upregulated in NEG greater than two-fold and found in the promoter or enhancer region of genes transcriptionally upregulated two-
fold in response to trametinib. (K) Volcano plot of the transcriptional response of NEG cells to acute trametinib treatment. Log2 fold 
change in gene expression in trametinib treated sample relative to DMSO control. Genes upregulated greater than two-fold 
highlighted in red. Significance estimated by analysis of biological triplicate RNA-Seq reads using DESeq2. Transcription factors 





Figure 12. Supplemental Figure : Differential Transcriptional and Epigenetic Response to Acute Trametinib Treatment in Epithelial 
and Mesenchymal Cells. (A) Cell cycle analysis of POS cells following acute trametinib treatment with 30 nM trametinib for 24 hours. 
G1 (light blue), S (medium blue), G2 (dark blue) frequencies determined by curve fitting using Watson method. (B) Cell cycle 
analysis of NEG cells following acute trametinib treatment with 30 nM trametinib for 24 hours. G1 (pink), S (red), G2 (dark red) 
frequencies determined by curve fitting using Watson method. (C) Peaks identified by MACS analysis of BRD4 ChIP-Seq of POS 
following treatment with 30 nM trametinib for 24 hrs (y) compared to DMSO control (x). Points > y=x+1 (solid line) are upregulated 
greater than two-fold in response to trametinib. Points < y=(x-1) (solid line) are downregulated greater than two-fold in response to 
trametinib. (D) Motifs enriched in summits of BRD4 peaks upregulated in POS greater than two-fold and found in the promoter or 
enhancer region of genes transcriptionally upregulated two-fold in response to trametinib. (E) Peaks identified by MACS analysis of 
BRD4 ChIP-Seq of NEG following treatment with 30 nM trametinib for 24 hrs (y) compared to DMSO control (x). Points > y=x+1 
(solid line) are upregulated greater than two-fold in response to trametinib. Points < y=(x-1) (solid line) are downregulated greater 
than two-fold in response to trametinib. (F) Motifs enriched in summits of BRD4 peaks upregulated in NEG greater than two-fold and 




ANXA8. Several of the terms identified in the calcium ion binding GO term co-occur in the PIP3 binding 
term, including SYT1 and ANXA8, suggesting that the upregulation is cooperative. In contrast, the NEG 
subpopulation is characterized by the enrichment of GO terms involved in PDGFR activation and collagen 
binding. Examining the underlying genes of these terms, we observe the enrichment of several collagen 
genes in the PDGF binding term such as COL1A1, COL3A1, COL1A2, as well as PDGFB and PDGFRB. 
We have previously shown that the upregulation of PDGFB and PDGFRB play a critical role in MAPK 
reactivation in triple negative breast cancer in response to MEK inhibitor (Duncan et al., 2012). However, 
we also observe the enrichment of genes involved in extracellular matrix and collagen binding, including 
DDR1, DDR2, ECM2, and ITGA11. Previous reports demonstrate that epigenetic remodeling at distal 
regulatory elements can enhance transcriptional activation in response to targeted therapy (Stuhlmiller et 
al., 2015). Therefore, we performed ChIP-Seq to identify regulatory elements enriched in response to 
trametinib treatment and associated with transcriptionally activated genes. We identified 14063 H3K27ac 
peaks in the POS subpopulation with a minimum of five reads in either the trametinib-treated samples or 
DMSO control. Following acute trametinib treatment, we identified 2503 peaks greater than two-fold 
upregulated compared to the DMSO control (Figure 11F). We performed motif enrichment analysis of 
promoter or enhance peaks associated with upregulated genes identified by RNA-Seq using the HOMER 
position-weighted matrix search algorithm to identify the unique regulatory elements that may control 
transcriptional activation (Heinz et al., 2010). Interestingly, we discovered that the consensus motif 
<AGGAAGT> belonging to epithelial-specific ETS-family transcription factors ELF3, ELF5 and EHF is 
enriched in these peaks following trametinib treatment. This search also revealed the enrichment of the 
consensus motif <TGA(G/C)TCA> belonging to the AP-1 family members FRA1 and FRA2. We 
hypothesized that enrichment of the consensus sequence may correlate with increased expression of the 
transcription factors that bind the regulatory elements. DESeq2 analysis of the transcriptional response to 
trametinib revealed increased expression of ELF3, EHF and FRA2 (Figure 11H). Notably, exclusion of 
peaks associated with genes that are upregulated in both POS and NEG subpopulations greatly reduced 
the enrichment of AP-1 motifs, indicating that AP-1 may mediate a common transcriptional response to 
trametinib. These results suggest that increased expression of AP-1 and ETS family transcription factors 
can facilitate p300 recruitment to promoter and enhancer regions to mediate the transcriptional response 
 
49 
to trametinib treatment. To further refine our search for distal regulatory elements associated with 
transcriptional activation in response to trametinib treatment, we performed ChIP-Seq for the histone  
acetylation reader BRD4. We identified 11240 BRD4 peaks in the POS subpopulation with a minimum of 
2 reads in either the trametinib treated or DMSO control samples (Figure 12C). We observe 1333 BRD4 
peaks that are upregulated at least two-fold in response to acute trametinib treatment of the POS 
subpopulation. Interestingly, unlike the motif searches performed on the H3K27ac ChIP-Seq, we observe 
an enrichment of AP-1 family motifs, including FRA2, JUNB, and FRA1, but not the epithelial-specific 
ETS-family transcription factors such as ELF3 and EHF (Figure 12D). In the NEG subpopulation, we 
identified 14456 H3K27ac peaks with a minimum of five reads in either the trametinib treated or DMSO 
control samples. Following acute trametinib treatment, we identified 1578 peaks greater than two-fold 
enriched relative to the DMSO control (Figure 11I). We performed motif enrichment analysis of promoter 
and enhancer peaks associated with genes transcriptionally upregulated in the NEG subpopulation in 
response to trametinib treatment. We identified enrichment of the <TGA(G/C)TCA> characteristic of AP-1 
family members, but we did not observe the enrichment of the ETS-family transcription factors that we 
identified in analysis of H3K27ac peaks induced in the POS subpopulation (Figure 11J). Examining the 
DESeq2 analysis of differentially expressed genes following trametinib treatment of the NEG 
subpopulation, we observe upregulation of several AP-1 family members, including JUNB, JUN, and 
JUND (Figure 11K). We also analyzed BRD4 binding in the NEG subpopulation in response to trametinib 
treatment. We identified 10970 peaks with a minimum of 2 reads in either the trametinib-treated or DMSO 
control samples (Figure 12E). We observed 2397 peaks were upregulated at least two-fold in the NEG 
subpopulation in response to trametinib treatment. We again identified the enrichment of the AP-1 family 
motif in BRD4 peaks upregulated in response to trametinib treatment. Previous studies have shown that 
the AP-1 motif is highly enriched at BRD4 binding sites, and AP-1 family members may facilitate 
recruitment of BRD4 to enhancer peaks to promote transcription of target genes (Najafova et al., 2017). 
These results suggest that recruitment of BRD4 to AP-1 binding sites following transcriptional activation 





Differential Response to Chronic Trametinib Treatment in Isolated Subpopulations 
Recent studies have shown that the frequencies of epithelial and mesenchymal subpopulations in 
circulating tumor cells of breast cancer patients change in response to treatment with targeted therapy 
(Yu et al., 2013). Furthermore, Risom et al. demonstrated that treatment with trametinib may induce cell-
state switching in basal-like breast cancer to resist the drug (Risom et al., 2018). This suggests that 
chronic treatment with targeted therapy applies a positive selective pressure for cells that readily adapt to 
the presence of the drug. Therefore, we interrogated the persistence of the acute adaptation to trametinib 
in the POS and NEG subpopulations during chronic treatment with 10 nM trametinib. POS and NEG 
subpopulations were treated continuously with 10 nM trametinib, and cell cycle progression was 
assessed by fixation followed by staining with propidium iodide and analysis by flow cytometry. The NEG 
subpopulation (Figure 13A) continued to proliferate during the course of chronic treatment, as indicated 
by the presence of the prominent G2 peak. However, similar to the acute response, the S and G2 peaks 
are nearly completely lost following trametinib treatment of the POS subpopulation (Figure 13B). We 
further quantified proliferation of POS and NEG subpopulations by plating 10,000 cells per well in a 6-well 
dish and continuously treating those cells with 10 nM trametinib. Cells were fixed and stained with crystal 
violet stain to identify drug resistant cells following treatment (Figure 13C). Increased staining at Day 21 
and 49 of treatment in the NEG subpopulation indicates that these cells continue to proliferate in the 
presence of the drug. Quantification of crystal violet absorbance demonstrates that the NEG 
subpopulation continues to proliferate in the presence of trametinib (Figure 14A). In the POS 
subpopulation, small drug-resistant colonies appear at Day 21 of treatment. Drug-resistant colonies 
observed at Day 49 are considerably larger than Day 21, suggesting that these cells have adapted to 
proliferate in the presence of trametinib (Figure 13C). We performed RNA-Seq of the POS and NEG 
subpopulations to determine the persistence of the adaptive response during the course of chronic 
trametinib treatment. In the NEG subpopulation, we captured 12,532 genes with at least one sample with 
a minimum of 25 reads. We identified 1441 genes (11%) that change at least two-fold during the course 
of chronic treatment (Figure 13D). We performed hierarchical clustering of differentially expressed genes 
and identified three distinct patterns in gene expression: genes that initially increase in response to 





Figure 13. Persistence of Acute Response in Chronic Treatment of Subpopulations. (A) Cell cycle analysis of NEG cells following 
chronic treatment with 10 nM trametinib every three days for up to 35 days beginning with Day 0 (pink) and ending with Day 35 
(dark red). (B) Cell cycle analysis of POS cells following chronic treatment with 10 nM trametinib every three days for up to 35 days 
beginning with Day 0 (light blue) and ending with Day 35 (dark blue). (C) Crystal violet staining of POS and NEG cells following 
chronic treatment with DMSO or 10 nM trametinib every three days for up to 49 days. (D) Heatmap of gene expression in NEG cells 
during chronic trametinib treatment. Heatmap displays log2 transformed, mean-centered, normalized mean gene expression of 
triplicate RNA-Seq values. Genes clustered by row using average linkage of Pearson’s correlation. Minimum heatmap value is 
white, maximum is red. Gene ontology analysis performed on each dendrogram branch using the Molecular Function GO terms in 
the Enrichr database. (E) Heatmap of gene expression in POS cells during chronic trametinib treatment. Heatmap displays log2 
transformed, mean-centered, normalized mean gene expression of triplicate RNA-Seq values. Genes clustered by row using 
average linkage of Pearson’s correlation. Minimum heatmap value is white, maximum is blue. Gene ontology analysis performed on 







Figure 14. Supplemental Figure : Persistence of Acute Response in Chronic Treatment of Subpopulations. (A) Quantification of 
absorbance at 600 nm of the crystal violet stain dissolved in an acetic acid solution relative to the Day 0 control. (B) Heatmap of 
expression of genes in PDGF Binding GO term in NEG cells during chronic trametinib treatment. Heatmap displays log2 
transformed, mean-centered, normalized mean gene expression of triplicate RNA-Seq values. Minimum heatmap value is white, 
maximum is red. (C) Heatmap of expression of genes in MAPK Y/S/T Phosphatase GO term in NEG cells during chronic trametinib 
treatment. (D) Heatmap of expression of genes in Actin Binding GO term in NEG cells during chronic trametinib treatment. (E) 
Heatmap of expression of genes in Tropomyosin Binding GO term in NEG cells during chronic trametinib treatment. (F) Heatmap of 
expression of genes in Integrin Binding GO term in NEG cells during chronic trametinib treatment. (G) Heatmap of expression of 
genes in PIP3 Binding GO term in POS cells during chronic trametinib treatment. Heatmap displays log2 transformed, mean-
centered, normalized mean gene expression of triplicate RNA-Seq values. Minimum heatmap value is white, maximum is blue. (H) 
Heatmap of expression of genes in PI3K Regulator Activity GO term in POS cells during chronic trametinib treatment. (I) Heatmap of 




and genes that continuously increase throughout treatment (UP). We analyzed the molecular function of 
these gene groups by GO analysis using the Enrichr database. Interestingly, the PDGF Binding GO term 
identified in the acute response to trametinib is significantly enriched in the Up-Down gene cluster, 
suggesting that the upregulation of PDGFB, PDGFRB, COL1A, and COL5A1 is a transient response to 
the loss of MAPK signaling in the NEG subpopulation (Figure 14B). In the DOWN gene cluster, GO 
analysis reveals the enrichment of several terms related to MAPK phosphatase activity (Figure 14C), 
suggesting that the NEG subpopulation maintains MAPK activation in the presence of trametinib by 
decreasing the expression of serine-threonine phosphatase that regulate MAPK activity. In the UP gene 
cluster, we identified the enrichment of several GO terms that involved in the regulation of F-actin, 
including actin binding and tropomyosin binding, and integrin binding (Figure 14D-F). These results 
indicate that in response to trametinib treatment, the NEG cells reinforces focal adhesions and associated 
stress fibers. In contrast to the NEG subpopulation, the POS subpopulation have a stronger 
transcriptional response to chronic treatment with trametinib. We captured 13,118 genes with at least 25 
reads, and identified 4,904 genes (37%) that change at least two-fold in response to chronic trametinib 
treatment (Figure 14E). When comparing the transcriptional response of the POS and NEG 
subpopulations, we observe a stronger transcriptional response in the POS (37% of expressed genes) 
compared to the NEG (11% of expressed genes). Furthermore, following hierarchical clustering of 
dynamic genes in the POS subpopulation, we do not observe the Up-Down gene class indicative of 
genes that acutely respond but return to control levels during chronic treatment. Instead, we simply 
observe two classes: genes that continuously decrease in expression during chronic treatment (DOWN), 
and genes that continuously increase in response to chronic treatment (UP). GO analysis of genes that 
decrease during chronic treatment show that many of these GO terms are associated with DNA 
replication, which does not occur in POS cells arrested in G1. POS cells also upregulate PIP3 binding 
and PI3K Regulator Activity (Figure 14G-H), suggesting that these genes may play a key role in 
mediating survival of POS cells during growth arrest with chronic trametinib treatment. Lastly, we observe 
the upregulation of genes regulating insulin receptor signaling, including IGFBP2, IGFBP3, IGFBP5, and 
INSR (Figure 14I). These data indicate decreased expression of genes regulating DNA replication occurs 
concomitant with G1 arrest in the POS subpopulation during chronic trametinib treatment, and survival of 
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POS subpopulation is mediated by PI3K and Insulin receptor activation. In comparison, we identified a set 
of genes in the NEG subpopulation that acutely increase in response to trametinib but return to basal 
expression levels, a gene expression pattern that is not observed in the POS subpopulation. GO analysis 
of genes that are downregulated in the NEG during chronic trametinib treatment revealed that MAPK 
activation in the NEG subpopulation may be mediated by the loss of serine-threonine phosphatases. 
 
Epigenetic Remodeling Persists in Response to Chronic Trametinib Treatment 
We performed ChIP-Seq of NEG and POS subpopulations following chronic treatment with 10 nM 
trametinib for two and five weeks to assess the durability of epigenetic remodeling. We identified 1017 
(9%) H3K27ac peaks upregulated in NEG cells at least two-fold at Day 14 (D14) and Day 35 (D35) out of 
11659 total H3K27ac peaks in the NEG subpopulation with a minimum of five reads (Figure 15A). We 
performed the same analysis for BRD4 ChIP-Seq of the NEG subpopulation, and we identified 1709 
(12%) BRD4 peaks upregulated at least two-fold at D14 and D35 out of a total 14728 peaks with a 
minimum of two reads (Figure 15B). Notably, we observed that almost all peaks that were upregulated at 
least two-fold at D14 remained two-fold upregulated at D35, indicating that the epigenetic response to 
trametinib is imprinted within the first two weeks of treatment and persists through five weeks of 
treatment. To identify the regulatory elements that may be controlling the epigenetic response to 
trametinib during chronic treatment, we identified 105 H3K27ac peaks classified as either promoter or 
enhancer peaks and associated with genes that are upregulated a minimum of two-fold at D14. We 
performed motif analysis of these peaks, which demonstrated very weak enrichment scores (Figure 15C). 
However, when we performed the same motif analysis of 130 peaks we identified in BRD4 ChIP-Seq, we 
observed significant enrichment of AP-1 motif family members AP-1, FOSL2, JUN, FOSL1, and FOSL2 
(Figure 15D). These motifs are more enriched in the chronic context compared to the acute context, 
suggesting that BRD4 plays an essential role in the maintenance of transcription of AP-1 targets during 
chronic trametinib treatment.  
We performed H3K27ac ChIP-Seq following chronic treatment of POS cells with 10 nM 






Figure 15. Epigenetic Remodeling in Response to Chronic Trametinib Treatment in Epithelial and Mesenchymal Subpopulations. 
(A) Comparison of H3K27ac density in NEG identified by MACS analysis of H3K27ac ChIP-Seq of NEG following chronic treatment 
with 10 nM trametinib at Day 14 (x) and Day 35 (y) relative to Day 0. Points greater than two-fold upregulated or downregulated 
(solid lines) at both Day 14 and Day 35 are highlighted in red. (B) Comparison of BRD4 density in NEG identified by MACS analysis 
of BRD4 ChIP-Seq of NEG following chronic treatment with 10 nM trametinib at Day 14 (x) and Day 35 (y) relative to Day 0. Points 
greater than two-fold upregulated or downregulated (solid lines) at both Day 14 and Day 35 are highlighted in red. (C) Motifs 
enriched at H3K27ac peak summits upregulated greater than two-fold at D14 relative to Day 0 in NEG cells and found in the 
promoter or enhancer region of genes transcriptionally upregulated two-fold at Day 14 relative to Day 0. (D) Motifs enriched at BRD4 
peak summits upregulated greater than two-fold at D14 relative to Day 0 in NEG cells and found in the promoter or enhancer region 
of genes transcriptionally upregulated two-fold at Day 14 relative to Day 0. (E) Comparison of H3K27ac density in POS identified by 
MACS analysis of H3K27ac ChIP-Seq of POS following chronic treatment with 10 nM trametinib at Day 14 (x) and Day 35 (y) 
relative to Day 0. Points greater than two-fold upregulated or downregulated (solid lines) at both Day 14 and Day 35 are highlighted 
in blue. (F) Comparison of BRD4 density in POS identified by MACS analysis of BRD4 ChIP-Seq of POS following chronic treatment 
with 10 nM trametinib at Day 14 (x) and Day 35 (y) relative to Day 0. Points greater than two-fold upregulated or downregulated 
(solid lines) at both Day 14 and Day 35 are highlighted in blue. (G) Motifs enriched at H3K27ac peak summits upregulated greater 
than two-fold at D14 relative to Day 0 in POS cells and found in the promoter or enhancer region of genes transcriptionally 
upregulated two-fold at Day 14 relative to Day 0. (H) Motifs enriched at BRD4 peak summits upregulated greater than two-fold at 
D14 relative to Day 0 in POS cells and found in the promoter or enhancer region of genes transcriptionally upregulated two-fold at 




of 12290 peaks with a minimum of five reads (Figure 15E). Similar to the pattern in the NEG cells, we 
observed that nearly all peaks upregulated at least two-fold at D14 continued to be upregulated at D35. 
Interestingly, we performed motif analysis on 909 H3K27ac peaks associated with upregulated genes, 
and we identified several members of the p53 transcription factor family, including TP73, TP63, and TP53 
in addition to AP-1 family members (Figure 15G). When considering the BRD4 peaks, we discovered that 
7710 peaks (57%), more than half of the 13613 peaks we identified with a minimum of two reads, were 
upregulated in response to chronic trametinib treatment. Similar to the acute response to trametinib in the 
POS cells, we observe a strong enrichment for the AP-1 family <TGAG/CTCA> motif in the 1723 
upregulated BRD4 peaks associated with transcriptionally upregulated genes. These results indicate that 
AP-1 family members recruit BRD4 to promoters and enhancers of transcriptionally activated genes 
during chronic trametinib treatment in both the POS and NEG subpopulations, similar to the response in 
the acute context. However, increased H3K27ac in the POS and NEG subpopulations appears to be 
more specific to the cell type, with increased acetylation at loci containing the epithelial-specific 
transcription factor TP63. 
 
Drug Resistant POS Cells Emerge Following Chronic Trametinib Treatment 
During chronic treatment, we observed that the NEG cells continued to proliferate while the POS 
cells were growth arrested. However, after approximately three weeks of chronic treatment with 10 nM 
trametinib, we observe small colonies of POS cells forming (Figure 13C). Therefore, we independently 
isolated two biological replicates of POS and NEG drug resistant cells following six weeks of treatment, 
and began chronic treatment with the higher dose of 30 nM trametinib used during acute treatment. 
Notably, when we escalated the dose to 30 nM trametinib, the NEG cells growth arrested but the drug-
resistant POS cells (POS R) continued to proliferate. We stained POS and NEG cells for senescence-
associated beta-galactosidase before and after dose escalation, and we observe prominent staining in 
the NEG cells that had been dose-escalated (Figure 16A, NEG R) but not the naïve cells that had never 
been exposed to trametinib (Figure 16A, NEG N). However, we do not observe significant staining in the 
drug resistant POS cells (Figure 16A, POS R) compared to the naïve cells (Figure 16A, POS N). 





Figure 16. Resistant Cells Emerge in the Epithelial Subpopulation. (A) Beta-galactosidase staining of POS naïve (POS N) and NEG 
naïve (NEG N) cells before chronic treatment with 10 nM trametinib, or beta-galactosidase staining of POS resistant (POS R) and 
NEG resistant (NEG R) following by dose escalation to 30 nM trametinib after six weeks of drug conditioning with 10 nM trametinib. 
(B) Tumor volume of xenograft following injection of 2 million POS naïve control (grey), POS naïve trametinib (blue) or POS 
resistant (navy) into the mammary fat pad of NSG mice. NSG mice injected with POS naïve cells were placed on 0.3 mpk/day 
trametinib chow once tumor volume reached 100 mm3. (C) Western blot for phosphorylation T202 and Y204 in the activation loop of 
ERK 1/2 to determine activity of MEK following treatment of POS Naïve and POS resistant cells with 30 nM trametinib. ERK2 used 
as loading control. (D) Cell cycle analysis of POS R1 and POS R2 cells compared to POS naïve cells following acute trametinib 
treatment with 30 nM trametinib for 24 hours. G1 (light grey), S (medium grey), G2 (black) frequencies determined by curve fitting 
using Watson method. (E) Crystal violet staining of POS R1 and R2 following chronic treatment with DMSO control or 10 nM 
trametinib every three days. (F) Volcano plot of differentially expressed genes in POS R1 cells relative to POS N cells. Log2 fold 
change in gene expression in POS R1 sample relative to POS N control. Genes upregulated greater than two-fold highlighted in 






cells (Figure 17A, grey) and six NSG mice on trametinib chow with 2 million NEG R cells (Figure 17A, 
red), and after ninety days, these mice had not developed xenograft tumors. We performed the same 
xenograft experiment with the POS cells, injecting twelve NSG mice on control chow with 2 million POS N 
cells, and six NSG mice on trametinib chow with 2 million POS R cells. Six mice in the control chow group 
were transferred to trametinib chow once the tumor volume reached approximately 100 mm3. POS N 
xenografts continued to proliferate in mice on control chow (Figure 16B, grey)6, but this proliferation was 
significantly reduced in POS N xenografts (Figure 16B, royal blue) in mice on trametinib chow. However, 
in mice on trametinib chow, the POS R xenografts (Figure 16B, navy blue) continue to proliferate at a rate 
similar to the POS N xenografts in mice on control chow (Figure 16B, grey). These results indicate that 
POS R cells have become resistant to trametinib, and continue to proliferate in presence of the drug. To 
determine if ERK has become reactivated in these POS R cells, we compared phosphorylation of the 
activation loop of ERK1/2 (T202/Y204) in the POS N treated with DMSO control or an acute dose of 30 
nM trametinib for 24 hours with both the POS resistant replicates, POS R1 and POSR2, treated 
continuously with 30 nM trametinib (Figure 16C). We observe that ERK phosphorylation is lost in POS N 
cells treated with the acute dose of trametinib compared to the DMSO control. However, ERK 
phosphorylation has returned in the POS R1 and POS R2 cells treated continuously with 30 nM 
trametinib. We performed cell cycle analysis to determine if POS R1 and POS R2 cells are proliferating in 
the presence of trametinib. We observe similar frequency of cells in G1 (Figure 16D, light grey) in the 
POS R1 (35%) and R2 (48%) as the POS N cells treated with DMSO control (30%). Furthermore, while 
treatment with 30 nM trametinib induces G1 arrest in POS N cells, POS R1 and POS R2 cells are actively 
proliferating, with a similar frequency of cells in S phase in POS R1 (51%) and POS R2 (38%) compared 
to the POS N untreated control (55%). We quantified proliferation of POS R1 and POS R2 during chronic 
                                                   
6Figure 16. (cont.) (G) Gene ontology analysis of genes transcriptionally upregulated in POS R1 cells using the Molecular Function 
GO terms in the Enrichr database. Combined score calculated using Enrichr database; log of p-value multiplied by z-score deviation 
from expected rank. (H) Heatmap of RSEM normalized H3K27ac reads using 5 bp bins ± 2 kb from the TSS of 345 genes identified 
by DESeq analysis in Fig. 6F. White corresponds to heatmap minimum, navy corresponds to heatmap maximum. Trace displays 
mean density of all rows in the column, average H3K27ac density increases at Day 35 (navy) relative to Day 14 (navy) and Day 0 
control (grey). (I) Heatmap of RSEM normalized BRD4 reads using 5bp bins ± 2kb from the TSS of 345 genes identified by DESeq 
analysis in Fig. 6F. White corresponds to heatmap minimum, navy corresponds to heatmap maximum. Trace displays mean density 





Figure 17: Supplemental Figure : Resistant Cells Emerge In Epithelial Subpopulation. (A) Tumor volume of xenograft following 
injection of 2 million NEG untreated control (grey) into the mammary fat pad of NSG mice on control chow and injection of 2 million 
NEG R following six weeks conditioning in 10 nM trametinib into the mammary fat pad NSG mice on trametinib chow (red). (B) Cell 
cycle analysis of POS N following treatment with DMSO control (grey) or 30 nM trametinib for 24 hours (blue) compared to POS R1 
cells continuously cultured in 30 nM trametinib (navy). (C) Cell cycle analysis of POS N following treatment with DMSO control 
(grey) or 30 nM trametinib for 24 hours (blue) compared to POS R2 cells continuously cultured in 30 nM trametinib (navy). (D) 
Volcano plot of differentially expressed genes in POS R2 cells relative to POS N cells. Log2 fold change in gene expression in POS 
R2 sample relative to POS N control. Genes upregulated greater than two-fold highlighted in navy. Significance estimated by 
analysis of biological triplicate RNA-Seq reads using DESeq2. (E) Venn diagram of the overlap of genes upregulated in POS R1 and 
POS R2 cells identified by DESeq. (F) Heatmap of genes upregulated in POS R1 cells identified by DESeq analysis, during chronic 





treatment by plating cells at low density and allowing continuous cell growth for 0, 14, or 21 days (Figure 
16E). We observed no crystal violet staining at Day 0, but visible staining at Day 14, and which intensifies 
at Day 21. These data confirm that the independently isolated POS R1 and POS R2 cells have developed 
resistance to trametinib, and are actively proliferating in the 30 nM trametinib dose that induced growth 
arrest of the POS cells with acute treatment. Therefore, we performed RNA-Seq to identify genes 
upregulated in the POS resistant cells that contribute to trametinib resistance. DESeq analysis of genes 
expressed in POS R1 cells compared to POS N cells revealed 345 genes that are upregulated in POS R1 
cells relative to POS N cells (Figure 16F). We analyzed the pathways activated by these 345 upregulated 
genes by performing GO analysis using the Molecular Function GO terms in the Enrichr database (Figure 
16G). This analysis revealed enrichment of genes regulated by PI3K activity including KITLG, IRS1, 
NRG1, PDGFB, FGF2 and FGFR2. Furthermore, we observe increased H3K27ac and BRD4 recruitment 
at the PIK3R1 locus, which correlates with increased transcription during chronic trametinib treatment 
(data not shown). To determine the role of epigenetic remodeling associated with these activated genes, 
we reexamined the H3K27ac ChIP-Seq of POS cells during chronic trametinib treatment, focusing on 
genes upregulated in POSR1 cells. We rank-listed the 345 genes by H3K27ac density at Day 0, then 
created a heatmap of H3K27ac density at the transcription start site at Day 0, Day 14 and Day 35 of 
treatment of POS cells with 10 nM trametinib (Figure 16H). These heatmaps reveal both an increase in 
H3K27ac generally, shown by increased intensity in each column, as well as specific enrichment of 
H3K27ac, where we can identify rows that exhibit increased H3K27ac at D14 and D35 that does not exist 
at Day 0. Furthermore, we quantified average H3K27ac density at Day 0 (Figure 16H, grey), Day 14 
(Figure 16H, blue), and Day 35 (Figure 16H, blue), which shows an increase in average H3K27ac density 
during chronic trametinib treatment. We performed similar analysis of BRD4 ChIP-Seq of POS cells 
during chronic trametinib treatment at the 345 genes upregulated in POS R1 cells, and identified a similar 
pattern observed in the H3K27ac ChIP-Seq data, with increasing BRD4 density during the course of 
chronic trametinib treatment, as well as specific enrichment of BRD4 by row at Day 14 and Day 35 
relative to Day 0 (Figure 16I). Finally, we analyzed the transcriptional pattern of resistance genes during 
the course of chronic trametinib treatment of POS cells (Figure 17D). Hierarchical clustering of these 
genes demonstrates that more than half of these genes (183 genes) continuously increase during the 
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course of chronic trametinib treatment, suggesting that epigenetic remodeling associated with these 
genes increases transcription to drive resistance in POS cells. 
 
Acquired Resistance and Epigenetic Remodeling Contribute to Trametinib Resistance 
Several studies have demonstrated that resistance to targeted kinase inhibitors can be inherent 
or acquired by either adaptation or selection of resistant cells (Bhullar et al., 2018; A. Lee and Djamgoz, 
2018; S. M. Miller et al., 2016; Rexer and Arteaga, 2012; Sale and Cook, 2014). In the emergence of 
resistant cells during chronic trametinib treatment, we can observe two modalities of resistance: the 
epigenetic adaptation to chronic trametinib treatment that increases expression of a gene that reactivates 
the MAPK pathway, as well as the selection of rare drug resistant cells during treatment. In the POSR1 
DESeq, we identified 345 genes that are significantly upregulated in the resistant cells relative to 
untreated naïve cells. DESeq analysis identified the G-protein coupled receptor, Atypical Chemokine 
Receptor 3, (CXCR7) and its cognate ligand, Adrenomedullin (ADM) as highly significant genes 
upregulated in trametinib resistant POS R1 cells (Figure 18A), and POS R2 cells (Figure 18A). Studies 
have shown CXCR7 is a Gi-coupled receptor that can activate MAPK signaling via beta-arrestin to 
stimulate survival and proliferation in breast cancer (Rajagopal et al., 2010; Salazar et al., 2014; Sobolik 
et al., 2014). While RNA-Seq of POS R1 and POS R2 suggest the overexpression of CXCR7 in these 
cells, we confirmed the expression of CXCR7 in both POS R1 and POS R2 cells by immunoblot (Figure 
18B). We reexamined the RNA-Seq data we collected during chronic trametinib treatment to determine if 
CXCR7 expression increases early in response to treatment, or emerges late in treatment as a result of 
selection. RNA-Seq analysis of CXCR7 expression demonstrates that in response to chronic trametinib 
treatment, CXCR7 levels increase approximately five-fold from 1173 reads to 5496 reads, and continue to 
increase throughout treatment to a maximum expression level of 16810 reads at Day 14 (Figure 18C). 
We examined ChIP-Seq for H3K27ac and BRD4 at the CXCR7 locus to determine the role epigenetic 
remodeling in the transcriptional activation of CXCR7. ChIP-Seq for BRD4 at the CXCR7 locus reveals 





Figure 18: KRAS and CXCR7 overexpression contribute to Trametinib Resistance. (A) Volcano plot of significant genes that are 
differentially expressed in POS R1 (navy) relative to POS N (blue). Increased expression of the chemokine receptor CXCR7 and its 
cognate ligand in POS resistant are highlighted in yellow. (B) Immunoblot for CXCR7 expression in POS N following treatment with 
DMSO or 30 nM trametinib for 24 hours compared to POS R1 and POS R2 continuously cultured in 30 nM trametinib. ERK2 is used 
as a loading control. (C) CXCR7 expression in response to chronic treatment with 10 nM trametinib every three days for 35 days. 
Gene expression is quantified by mean normalized RNA-Seq reads of three biological replicates. (D) Sashimi plot of BRD4 density 
at CXCR7 promoter following chronic treatment of POS cells at Day 0 (grey), Day 14 (light purple), and Day 35 (dark purple), as well 
as H3K27ac density at CXCR7 promoter following chronic treatment of POS cells at Day 0 (grey), Day 14 (light green), Day 35 (dark 
green). (E) Total cell count per well following 72 hour treatment of POS naïve with 30 nM trametinib in combination with siRNA 
control (solid) or siRNA knockdown of CXCR7 (checkered). (F) Total cell count per well following 72 hour treatment of POS resistant 
with 30 nM trametinib in combination with siRNA control (solid) or siRNA knockdown of CXCR7 (checkered). (G) Volcano plot of 
significant genes that are differentially expressed in POS R1 (navy) relative to POS N (blue). Increased expression of KRAS in POS 
resistant cells is highlighted in yellow. (H) Immunoblot for KRAS in POS N following 24 hr treatment with DMSO or 30 nM trametinib 
compared to POS R1 and POS R2 continuously cultured in 30 nM trametinib. 
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(Figure 7D, dark purple). Furthermore, ChIP-Seq for H3K27ac at the CXC7 locus also demonstrates 
increased histone acetylation at both D14 (Figure 18D, light green) and D35 (Figure 18D, dark green). To 
determine the role of CXCR7 in POS R1 proliferation and survival, we quantified cell proliferation 
following siRNA knockdown of CXCR7 in POS N and POS R1 cells. Interestingly, CXCR7 knockdown in 
the POS N cells has no significant effect on proliferation relative to the non-targeting control (Figure 18E). 
However, CXCR7 knockdown in the POS R1 cells significantly decreases proliferation (Figure 18F), 
indicating that CXCR7 plays an essential role in mediating trametinib resistance. Additionally, DESeq 
analysis of POS R1 cells revealed that KRAS is significantly upregulated in trametinib resistant cells 
relative to the untreated control in both POS R1 (Figure 18G) and POS R2 (Figure 19B). To confirm the 
upregulation of KRAS in trametinib resistant cells, we performed an immunoblot for KRAS and compared 
KRAS expression in POS N treated with either DMSO or 30 nM trametinib with KRAS expression in POS 
R1 and POS R2 cells (Figure 18H). These results show markedly higher expression of KRAS in both the 
POS R1 and POS R2 cells relative to POS N control or trametinib-treated samples. We confirmed KRAS 
expression in POS N and POS R1 contribute to survival and proliferation by measuring cell proliferation 
following treatment with siRNA targeting KRAS and a non-targeting control (Figure 18I and 18J)7. To 
determine if KRAS expression immediately increases in response to trametinib, we reexamined KRAS 
RNA-Seq reads at D0, D1, D14 and D35 of treatment in POS cells, but unlike CXCR7, we did not observe 
a substantial increase in KRAS expression during chronic treatment (Figure 19C). Therefore, we 
hypothesized that chronic trametinib treatment may select cells in the untreated POS population that 
express high levels of KRAS, and these elevated levels of KRAS mediate survival and proliferation in the 
presence of the drug. To determine if cells expressing high levels of KRAS exist in the untreated POS 
population, we performed KRAS RNA-FISH in POS N and POS R1 (Figure 18K). We observed a broad 
distribution of KRAS expression in the POS R1 population, with 14% of the cells classified with low  
                                                   
7 Figure 18: (cont.) (I) Total cell count per well following 72 hour treatment of POS naïve with 30 nM trametinib in combination with 
siRNA control (solid) or siRNA knockdown of KRAS (checkered). (J) Total cell count per well following 72 hour treatment of POS 
resistant with 30 nM trametinib in combination with siRNA control (solid) or siRNA knockdown of KRAS (checkered). (K) RNA FISH 
probe targeting KRAS in POS N and POS R1 cells (red), nuclei stained with DAPI (blue). (L) RNA FISH probe targeting KRAS in 
POS cells (red), following chronic trametinib treated for 49 days with 10 nM trametinib. Nuclei stained with DAPI (blue). (M) 
Quantification of unique transcripts captured per cell (UMI) in scRNA-Seq. POS R1 (navy) cells are rank-listed from highest to 





Figure 19. Supplemental Figure : KRAS and CXCR7 overexpression contribute to Trametinib Resistance. (A)Volcano plot of 
significant genes that are differentially expressed in POS R2 (navy) relative to POS N (blue). Increased expression of the chemokine 
receptor CXCR7 and its cognate ligand in POS resistant are highlighted in yellow. (B) Volcano plot of significant genes that are 
differentially expressed in POS R2 (navy) relative to POS N (blue). Increased expression of KRAS in POS resistant cells is 
highlighted in yellow. (C) KRAS expression in response to chronic treatment with 10 nM trametinib every three days for 35 days. 
Gene expression is quantified by mean normalized RNA-Seq reads of three biological replicates. (D) Classification of cells in POS N 
(grey) and POS R1 (navy) into low, medium, and high expression groups following staining for KRAS expression using a KRAS 
RNA-FISH probe. (E) Distribution of KRAS expression in POS N (grey) and POS R1 (navy) cells by scRNA-Seq. Cells were sorted 





expression, 23% classified with medium expression, and 62% classified with high expression (Figure 
19D, navy). In comparison, the untreated POS subpopulation has more uniformly low expression, with 
99% of cells classified with expression below threshold (Figure 19D, grey). Interestingly, when we treated 
cells continuously for 35 days with 10 nM chronic trametinib treatment, we discovered that these colonies 
were not significantly enriched in KRAS positive cells, suggesting this adaptation occurs after dose 
escalation to 30 nM trametinib (Figure 18L). Furthermore, we performed single-cell RNA sequencing on 
the POS N and POS R1 cells to quantify single-cell gene expression of KRAS in these two populations. 
These results show a broad distribution of KRAS expression in POS R1 cells with an average of 25.2 ± 
18.1 reads, whereas KRAS expression in POS N cells is more uniformly low, with an average of 2.1 ± 1.9 
reads (Figure 18M and Figure 19E). These results suggest that KRAS expression does not uniformly 
increase in response to trametinib treatment, and that cells that preexist in the untreated POS 
subpopulation are inherently more resistant to chronic trametinib treatment, and continue to proliferate in 
the presence of the drug. These two modalities of resistance to trametinib treatment suggest that 
epigenetic remodeling in response to targeted therapy can enhance transcription of genes to reactive 
MAPK signaling, and contribute to the proliferation and survival of cells that are inherently more resistant 
to the drug. 
 
Materials and Methods 
Cell Culture 
Low passage SUM-229PE and isolated subpopulations were cultured in Ham’s F-12 Media 
(Gibco cat. # 11765-054) with 5% fetal bovine serum (VWR cat. # 97068-085), 5 µg/mL insulin (Gibco cat. 
# 12585-014), 1 µg/mL hydrocortisone (Sigma cat. # H0396), 1% penicillin-streptomycin solution (Gibco 
cat. # 15140-014) and 5 mM HEPES (Corning cat. # 25-060-CI). SUM-229 POS R1 and POS R2 were 
continuously cultured in 10 nM trametinib for six weeks, changing the media every three days. These 
cells were then trypsinized and dose escalated to 30 nM trametinib. POS R1 and POS R2 cells were 





Whole Exome Sequencing Analysis 
Nextera Rapid Capture whole exome sequencing data for SUM229 EpCAM/CD49f positive or 
negative sorted populations was aligned to GRCh37/hg19 using BWA-MEM v 0.7.9a using -Y -M -R 
options and duplicates were subsequently marked using Biobambam v 0.0.172. ABRA (Mose et al., 2014) 
realignment was employed for indel detection and to improve variant allele frequency estimation. The 
resulting ABRA .bam files were piped to FreeBayes (Garrison and Marth, 2012) v 1.1.0-54 for generation 
of a germline variant call file whereby SUM-229 positive and negative samples were unified by nucleotide 
variant position. VCFtools (Danecek et al., 2011) v 0.1.15 was employed to limit variant call file entries to 
Nextera Rapid Capture targeted regions. Variants were annotated using SNPEff (Cingolani et al., 2012) v 
4.3t and only variants supported by a Quality score of >30 were considered for tabulation and plotting. 
Common variants or variants unique to either subpopulation were then visualized using Circos 
(Krzywinski et al., 2009) v. 0.69-4, where alleles for a given nucleotide position were plotted as a 
heatmap. Non-synonymous coding changes or frameshift changes were highlighted in a concentric ring to 
distinguish from synonymous coding changes and other SNPEff annotations of predicted low functional 
effect. 
 
Cell Lysis and Immunoblotting 
KRAS expression was detected using a mouse polyclonal anti-human KRAS antibody (Santa 
Cruz cat. # sc-30). CXCR7 expression was detected using a rabbit polyclonal anti-human CXCR7 
antibody (Proteintech cat. # 20423-1-AP). ERK2 expression was detected using a rabbit polycolonal 
ERK2 antibody (Santa Cruz cat. # sc-154). Rabbit primary antibodies were detected using an HRP-
conjugated donkey anti-rabbit secondary antibody (Jackson Laboratories cat. # 711-035-152). Mouse 
primary antibodies were detected using an HRP-conjugated goat anti-mouse secondary antibody 
(Invitrogen cat. # 31432). Media was aspirated and plate was washed 1X with ice-cold PBS, then plate 
was aspirated again. 250 µL of lysis buffer (20 mM Tris-HCl, pH 8.0, 1% NP-40, 10% glycerol, 137 mM 
NaCl, 2 mM EDTA, 2.5 mM NaVO4, 1 EDTA-free protease inhibitor cocktail tablet per 25 mL (Roche cat. 
# 11873580001), 1% phosphatase inhibitor cocktail 2 (Sigma cat. # P5726), and 1% phosphatase 
inhibitor 3 (Sigma cat. # P0044)) was added to plate and cells were scraped from the plate using a cell 
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lifter, then lysed by vigorously pipetting cells up and down. Cell debris was pelleted at 16,000 x g, and 
supernatant was transferred to a new tube. Protein concentration was calculated by Bradford Assay using 
a bovine serum albumin standard solution. 50 µg of lysate was added to each lane of 8% SDS-PAGE gel, 
and run at 120V for approximately 2 hrs. Gel was transferred overnight to nitrocellulose membrane in 
transfer buffer (25 mM Tris-HCl, 192 mM glycine, pH 8.3 with 20% methanol) at constant current of 180 
mA. Membranes were blocked for 1 hr with TBST (50 mM Tris-HCl, 150 mM NaCl, pH 7.5, 0.1% Tween-
20) + 5% powdered milk, washed three times with TBST, then incubated overnight in primary antibody 
diluted 1:1000 in TBST + 5% milk. Membranes were washed three times with TBST, then incubated for 1 
hr in secondary antibody diluted 1:5000 in TBST + 5% milk. Membranes were washed three times, then 
developed using SuperSignal Pico Plus Chemiluminescent Substrate (Thermo Fisher cat. # 34577). 
Membranes were imaged using the BioRad Chemidoc Touch Imaging System.  
 
RNA Sequencing 
10 cm plates were aspirated and washed with PBS, then 600 µL of RPE Buffer Plus with 2-
mercaptoethanol was added to the plate. Cells were scraped using a cell lifter and then lysed by 
mechanical disruption using a 20 gauge needle. Total RNA was isolated using the RNeasy Plus Kit 
(Qiagen cat. # 74134). RNA Sequencing library was prepared with 4 µg of total RNA using KAPA 
stranded mRNA Sequencing kit (Roche cat. # 07962193001) and Illumina TruSeq sample indexes 
following the manufacturer’s protocol with the following exception: half of the adapter-ligated purified 
cDNA library was amplified with 10 cycles of PCR. The remaining library was stored at -20°C. Samples 
were pooled and sequenced as a 12-plex library pool using the 75-cycle NextSeq 500/550 High Output v2 
sequencing kit (Illumina cat. # FC-404-2005) on the Illumina NextSeq500 to yield approximately 4 x 107 
reads per sample. 
 
Chromatin Immunoprecipitation Sequencing 
ChIP-Seq for H3K27ac was performed using the ChIP-grade antibody for histone H3K27ac 
(Active Motif cat. # 39133). ChIP-Seq for BRD4 was performed using the ChIP-grade antibody for BRD4 
(Bethyl Laboratories cat. # A301-985A). Fixation and immunoprecipitation were performed as previously 
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described (Lovén et al., 2013; Zawistowski et al., 2017). Briefly, cells were fixed with 1% formaldehyde for 
10 minutes at room temperature, then quenched for five minutes using 1 mM Glycine. Media was 
discarded and cells were scraped on ice using a cell lifter. Cells were centrifuged 3K RPM at 4°C, then 
supernatant was aspirated and the pellet was flash frozen in liquid nitrogen. Antibody was conjugated to 
Protein A Dynabeads (Life Technologies cat. # 1002D) for 4 hours at 4°C in PBS + 0.5% BSA. 
Crosslinked pellets were resuspended in lysis buffer 1 to permeabilize plasma membrane, and 
centrifuged for 5 minutes at 4°C at 200 x g. Nuclei were resuspended in lysis buffer 2, and centrifuged for 
5 minutes at 4°C at 200 x g. Chromatin was resuspended in sonication buffer, sonication beads added 
and chromatin was sonicated at 4°C for 15 cycles; 30 seconds on, 30 seconds off. Beads were then 
washed three times with a low salt sonication buffer, then washed once with a high salt sonication buffer, 
then washed once with a LiCl wash buffer, then washed once with TE buffer. Fragmented chromatin was 
eluted from the beads with elution buffer at 65°C for 15 minutes, vortexing every two minutes. Eluted 
chromatin and Dynabeads were placed on the magnet, and eluted chromatin was transferred to a fresh 
tube. Crosslinking was reversed by incubating the eluted chromatin at 65°C overnight. The following day, 
0.2 µg/mL RNase A (Sigma cat. # R4642) was added to the samples and incubated for 1 hr at 37°C. 
Protein in the sample was digested using 0.2 µg/mL Proteinase K (Ambion cat. # 25530-015) at 55°C. 
Fragmented DNA was purified using the Qiagen MinElute Kit (Qiagen cat. # 28004). 50 ng of DNA was 
used for library preparation using the KAPA stranded HyperPrep Kit (Roche cat. # 07962347001) and 
Illumina TruSeq Indexed Adapters according to the manufacturer’s instructions. Dual size selection was 
performed after 18 cycles of PCR amplification of the cDNA library according to manufacturer 
recommendations. A multiplexed pool of 12 libraries was sequenced using the 75-cycle NextSeq 500/550 
High Output v2 sequencing kit (Illumina cat. # FC-404-2005) on the Illumina NextSeq500 to yield 
approximately 3.5 x 107 reads per sample. Python scripts written for alignment and peak calling are 
available on Github (Singh et al., n.d.). 
 
Motif Analysis 
H3K27ac or BRD4 Peaks identified by MACS that were upregulated two-fold in response to drug 
treatment with a minimum of 5 reads in H3K27ac peaks in trametinib-treated sample or 2 reads in BRD4 
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peaks in the trametinib treated sample were classified as upregulated peaks. Peaks +/- 5 kb of a gene 
TSS were classified as promoter peaks. Peaks located within 200 kb 5’ of a gene TSS or 200 kb 3’ of a 
gene TES, but not located in the promoter region or gene body were classified as enhancer peaks. 
Promoter and enhancer peaks that were upregulated with trametinib treatment and associated with genes 
that were transcriptionally upregulated greater than two-fold were classified as epigenetic activators. A 
400 bp window centered on the summits of epigenetic activator peaks was identified using the 
“refinepeak” option of MACS (version 2.1.2). Known consensus motifs enriched in the summits of 
epigenetic activator peaks were identified using the “findMotifsGenome.pl” package of Homer (version 
4.10) (Heinz et al., 2010). 
 
Cell Cycle Analysis 
Approximately 1 million cells were plated in a 10 cm tissue culture plate, and treated for the time 
indicated. Treated cells were washed with PBS, trypsinized for 5 minutes, then quenched with media. 
Cells were pelleted at 200 x g, and media was aspirated. Cells were resuspended in 300 uL 50% FBS in 
PBS. Ice-cold 70% ethanol was added dropwise, and cells were fixed overnight at 4°C. Fixed cells were 
pelleted at 200 x g, then washed twice with PBS, and resuspended the fixed cells in 500 µL of a 
propidium iodide solution (BD Biosciences cat. # 556463). Propidium iodide staining was measured by 
quantifying peak area of each cell using flow cytometry running Summit flow cytometry software (version 
4.3) on the Cyan ADP Flow Cytometer (Beckman Coulter). Data was normalized by adjusting the PE-
TexRd channel voltage so that the mean of the G1 peak measured 100 counts. Cell cycle analysis was 
performed using FlowJo (version 10.0.8). Cells were gated to remove dead and doublet cells, then 
frequency of each cell cycle phase was determined using the Watson method in the cell cycle analysis 
package of FlowJo. 
 
Fluorescence-Activated Cell Sorting 
Approximately 50 million SUM-229PE cells were used for fluorescence-activated cell sorting 
(FACS). Media was aspirated from the plates and cells were washed with PBS. Cells were trypsinized for 
approximately 5 minutes with 0.05% Trypsin-EDTA solution (Gibco cat. # 25300054), then resuspended 
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in HF Media (Hank’s Balanced Salt Solution (Gibco cat. # 14025092) with 2% FBS and 5 mM EDTA). 
Cells were resuspended in 1 mL of HF media at a concentration of 1 x 106 cells/mL and stained with 50 
uL of EpCAM (EpCAM-FITC, Stem Cell Technologies cat. # 60136FI) and 10 uL of CD49f (CD49f-PE-
Cy5, BD Biosciences cat. #551129) antibodies for 30 minutes in the dark at 4°C. Cells were pelleted at 
200 x g, and media was aspirated. Cells were washed twice with 10 mL of HF media, then filtered with a 
30 µm sterile cell strainer (Partec cat. # 04-004-2326). EpCAM-positive, CD49f-positive cells and EpCAM-
negative, CD49f-negative cells were sorted at single-cell purity using the FACSDiva software on the BD 
FACS Aria II. 
 
Crystal Violet Colony Formation Assay 
10,000 cells per well were plated in 6-well plates with three replicates for each condition at each 
timepoint. Media was changed every three days throughout the treatment period. Following treatment, 
cells were washed with PBS, fixed with ice-cold methanol for 10 minutes at -20°C, then stained for 20 
minutes with a 20% methanol solution containing 0.5% crystal violet dye. Stain was aspirated, and wells 
were rinsed and dried before imaging. Stain was solubilized in 1 mL of 30% acetic acid solution, and 
absorbance of dye from each well was measured at 600 nm. 
 
Xenograft Growth Assay 
All mice were treated in accordance with protocols approved by the Institutional Care and Use 
Committee for animal research at The University of North Carolina. Female NOD scid gamma mice were 
given a mammary fat pad injection of 2 x 106 POS, POS R1, NEG, or NEG R cells suspended in 50% 
Matrigel. Tumor volume was calculated by caliper measurements ((width)2 x (length)) / 2 every three days 
until tumors reached 100 mm3, at which point mice were given control chow or 0.3 mg/kg/day trametinib 
chow. Mice injected with trametinib resistant cell lines POS R1 and NEG R were given 0.3 mg/kg/day 
trametinib chow three days before xenograft injection and remained on trametinib chow through the 
duration of the study. Number of mice for each arm of the xenograft study: POS on control chow (n=6), 
POS on trametinib chow (n=6), NEG on control chow (n=12), POS R1 on trametinib chow (n=6), NEG R 
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on trametinib chow (n=6). Tumor volume of NEG and NEG R tumors did not reach the 100 mm3 minimum 
volume, and after 90 days the NEG and NEG R arms of the study were terminated.  
 
Beta-Galactosidase Staining 
Cells were stained using Senescence b-Galactosidase Staining Kit (Cell Signaling Technology 
cat. # 9860) according to the manufacturer’s instructions. Briefly, cells were cultured in a 35 mm cell 
culture dish. Media was aspirated and cells were washed with PBS. Cells were fixed for 10-15 minutes at 
room temperature using 1 mL of the 1X Fixative Solution prepared as recommended. Plate was rinsed 
twice with PBS, then 1 mL of the b-Galactosidase Staining Solution was added to the plate, which was 
sealed with parafilm and incubated overnight at 37°C in a dry incubator. Plates were stored in 70% 
glycerol at 4°C. 
 
siRNA Transfection 
Individual siRNA from siGENOME smartpools targeting CXCR7 (GE Dharmacon cat. # MQ-
013212-03-0002) and KRAS (GE Dharmacon cat. # MQ-005069-00-0002) were resuspended in siRNA 
buffer (GE Dharmacon cat. # B-002000-UB-100). Cells were transfected using RNAiMAX (Invitrogen cat. 
# 13778-075) with 25 nM siRNA. siGENOME non-targeting pool #2 was used as control siRNA (GE 
Dharmacon cat. # D-001206-14-05). Cells were incubated for 48 hours to ensure target knockdown, and 
RNA was isolated using the RNeasy Plus RNA isolation kit (Qiagen cat. # 74134). RNA was converted to 
cDNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems cat. # 4368813), then 
target expression was assessed by quantitative real-time PCR using taqman probes targeting KRAS 
(Hs00364284_g1) and CXCR7 (Thermofisher cat. # Hs00664172_s1) compared to ACTB control 
(Thermofisher cat. # Hs01060665_g1) and Taqman Fast Universal PCR Master Mix (Thermofisher cat. # 
4352042). The siRNA with the best results was selected for future studies.  
 
Cell Proliferation Assay  
Cells were plated in a 96-well plate and transfected with 25 nM of siRNA targeting KRAS or 
CXCR7. Cells were incubated for 24 hours following transfection, then media was aspirated. Cells were 
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treated with 30 nM trametinib for 72 hours, then stained with Hoescht 33342 at 2.5 µg/mL for 30 minutes 
at 37°C. Plates were imaged using a Thermo Cellomics ArrayScan VTI, capturing 25 frames per well. Cell 
number was quantified and siRNA target was compared siRNA control. 
 
RNAscope detection of KRAS RNA 
KRAS RNA was detected using the RNAscope® 2.5 LS Probe for Hs-KRAS-O1 (ACD Biotechne 
cat. # 522968) in a Bond RX autostainer (Leica Biosystems) following the manufacturer’s directions. TSA-
Cy5 and DAPI were used to visualize RNAScope signal and nuclei, respectively. 
 
Scanning and analysis of IF images 
Slides containing RNAscope fluorescently labeled cells were scanned either in the Aperio 
ScanScope FL or the Aperio Versa Digital Pathology Scanner using a 20X objective (Leica Biosystems). 
Images were archived in TPL’s eSlide Manger database (Leica Biosystems). Images were manually 
annotated for regions of interest using Tissue Studio software (Definiens Inc.Tissue Studio version 2.7 
with Tissue Studio Library version 4.4.2), specifically the Nuclei and Simulated Cells algorithm in the IF 
Portal, was then used to detect and enumerate cells that contained the cy5-labeled KRAS RNA. Briefly, 
nuclei were digitally detected by the presence of DAPI stain (nuclear counterstain). From these nuclei, a 
cell simulation was performed, and cells margins were grown out from nuclear boundaries. Positivity 
thresholds for KRAS RNA probe were determined by measuring the staining intensities both inside and 
outside simulated cells. Once thresholds were set, the algorithm evaluated each cell individually for the 
presence of KRAS RNA positive signal. Cells were separated by the algorithm into negative, low positive, 
medium positive, or high positive categories based on the signal intensity. H-Score values were 
determined using the following formula: [1 × (% cells 1+)] + [2 × (% cells 2+)] + [3 × (% cells 3+)].  
 
Single Cell RNA Sequencing 
Single cell RNA Sequencing of approximately 5000 POS cells and 5000 POS R1 cells was 
performed according to the manufacturer specification (10X Genomics cat. # 1000092, 1000074, 120262) 
Briefly, media was aspirated and cells were washed with PBS, then trypsinized with 0.05% Trypsin for 5 
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minutes. Media was added to stop digestion and cells were centrifuged at 200 x g for 5 minutes. Cells 
were resuspended in 1 mL of media, then filtered with a 30 µm filter and counted. Cells were washed 
twice with 0.04% BSA, then strained using a FlowMi tip strainer (Sigma cat. # BAH136800040) to 
minimize sample loss. Single cell libraries were prepared according to the manufacturer’s instructions. 
Library concentration was calculated by Agilent Tapestation, and library was amplified using 8 cycles of 
PCR according to manufacturer’s recommendation. Library was sequenced using the 150-cycle NextSeq 
500/550 High Output v2.5 sequencing kit (Illumina cat. # 20024907) on an Illumina NextSeq 500 
Sequencer. The cellranger mkfastq pipeline of 10x Genomics Cell Ranger v. 2.1.0 software was utilized 
to demultiplex 3’ Chromium v2 sequence reads. The resulting FASTQ files were piped to cellranger 
count for alignment, filtering, barcode counting, and UMI counting to generate the gene-barcode matrix 
for single-cell KRAS expression estimates of each SUM-229 subpopulation.  
 
Discussion 
A pathological partial response in triple negative breast cancer patients can be caused by tumor 
heterogeneity resulting from chromosomal instability or epigenetic plasticity that allows cell switching to a 
drug tolerant state. In this study, we use the epithelial and mesenchymal subpopulations of a cell line 
isolated from a TNBC patient to examine the role of cell state in epigenetic remodeling following treatment 
with the MEK inhibitor trametinib. Analysis of the whole exome sequencing of the POS and NEG 
subpopulations using a germline variant caller highlights the genetic similarity of these two 
subpopulations, suggesting that these two phenotypes are epigenetically regulated. Indeed, a previous 
study using these POS and NEG subpopulations demonstrated that siRNA knockdown of SMARCD3, a 
regulatory subunit of the SWI/SNF chromatin remodeling complex, is sufficient to induce a switch from the 
NEG to POS phenotype (Jordan et al., 2013). SMARCD3 knockdown in the NEG subpopulation induces 
loss of SNAIL and SLUG, indicating that the SWI/SNF chromatin remodeling complex plays an important 
role in maintaining the expression of these mesenchymal-specific transcription factors. The role of 
epigenetic regulation of cell identity can be observed in the enrichment of H3K27ac and BRD4 peaks 
associated with transcription factors TWIST1 and ZEB1 in the NEG subpopulation that maintain the 
mesenchymal phenotype, and TP63 and ELF3 in the POS subpopulation that maintain the epithelial 
 
74 
phenotype. Previous studies have shown that knockdown of ZEB1 is sufficient to induce expression of E-
Cadherin and desmoplakin concomitant with loss of mesenchymal markers SNAIL1 and SNAIL2 (An et 
al., 2017). An analogous study demonstrated that knockdown of TP63 is sufficient to induce an epithelial 
to mesenchymal transition in breast cancer cells, demonstrating the role of TP63 in the maintenance of 
the epithelial phenotype (Lindsay et al., 2011). RNA-Seq analysis of POS and NEG isolated 
subpopulations revealed elevated expression of MET in both the POS and NEG subpopulations, which 
had been observed in previous studies of SUM-229 PE cells. However, we also observed subpopulation 
specific expression of tyrosine kinases PDGFRa and AXL in the NEG subpopulation, whereas we 
observed specific expression of EGFR and SRC in the POS subpopulation. The differential expression of 
these tyrosine kinases likely governs the proliferation of these two subpopulations, as the POS 
subpopulation is more proliferative but more sensitive to trametinib, whereas the NEG subpopulation is 
less proliferative but also less sensitive to trametinib.  
Cancer cells can rapidly remodel chromatin in response to targeted therapy to enhance 
transcription of genes that mediate drug resistance. Analysis of the transcriptional response in a panel of 
breast cancer cell lines demonstrated that while some genes were commonly upregulated in all cell lines, 
some genes were specifically upregulated in mesenchymal or epithelial cell lines (Zawistowski et al., 
2017). In the context of a heterogenous tumor, these distinct transcriptional responses in epithelial and 
mesenchymal cells can have a profound impact on outcome, as these unique responses may not be 
discretely targeted by monotherapy. Therefore, we used the isolated subpopulations of the heterogenous 
triple negative breast cancer cell line SUM-229 PE to identify the unique regulatory elements that control 
the epigenetic response to acute trametinib treatment. Interestingly, motif analysis of upregulated 
H3K27ac promoter or enhancer peaks associated with genes upregulated in the POS subpopulation 
identified several epithelial-specific ETS-family transcription factor motifs. It is well established that MAP 
kinases can directly phosphorylate ETS-family transcription factors, which act as effectors of MAPK 
signaling (Plotnik et al., 2014; Selvaraj et al., 2015). Furthermore, biochemical studies of ETS-family 
transcription factors demonstrated that the histone acetyltransferase p300 preferentially binds to 
phosphorylated ETS-1 and ETS-2, suggesting that these transcription factors play an essential role in 
remodeling H3K27ac in response to targeted therapy in epithelial cells by recruiting p300 to target genes 
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(Foulds et al., 2004). Strikingly, motif analysis of the upregulated BRD4 promoter and enhancer peaks 
revealed enrichment of only AP-1 family motifs <TGAG/CTCA> in the most highly enriched sequences. 
Genome-wide analysis of BRD4 binding has demonstrated that this transcriptional coactivator specifically 
localizes with AP-1 family members FOSL2 and JUND at enhancers (Najafova et al., 2017). These results 
are supported by the finding that BRD4 binds direct to c-Jun (S.-Y. Wu et al., 2013). Furthermore, siRNA 
knockdown of either FOSL2 or JUND decreases BRD4 binding at these enhancers and decreases 
transcription of target genes. This indicates that AP-1 family members can recruit BRD4 to enhancers to 
stimulate transcription of target genes and increase survival in the presence of the drug. Surprisingly, 
motif analysis of the H3K27ac peaks in the NEG subpopulation did not reveal any motifs unique to this 
subpopulation, but did identify the enrichment of the AP-1 family motif. This suggests that several factors 
beyond DNA sequence can control epigenetic remodeling in response to targeted therapy, such as 
chromatin accessibility and structure. Similar to the motif enrichment of BRD4 peaks in the POS 
subpopulation, analysis of upregulated BRD4 peaks associated with genes upregulated in the NEG 
subpopulation revealed that the most highly enriched motifs belong to AP-1 family members. This 
indicates that BRD4 can be recruited by AP-1 family members in either the POS or NEG subpopulation to 
stimulate gene transcription in response to trametinib treatment, suggesting a universal role for BRD4 in 
growth signaling.  
While acute drug treatments offer a tractable approach to study the response to targeted therapy, 
this approach cannot capture the chronic adaptation to continued therapy that may occur during a clinical 
treatment regimen. Therefore, we treated POS and NEG subpopulations continuously during a five week 
treatment window to determine how cells adapt to chronic treatment. Similar to the acute response to 
trametinib, we observed that the NEG cells continued to proliferate in the presence of trametinib in both 
cell cycle analysis and crystal violet assays. GO analysis of the transcriptional response to chronic 
treatment with trametinib demonstrates that NEG cells upregulate TGFb signaling, which can activate 
MAPK signaling in mesenchymal cells via PAK2 in a SMAD-independent manner (Suzuki et al., 2007; 
Wilkes et al., 2005). These results indicate that the NEG cells can stimulate MAPK signaling by activation 
of autocrine signaling of the TGFb receptor, a pathway that is unable to be activated in the POS epithelial 
cells. Activation of MAPK signaling in NEG cells is further stimulated by the downregulation of dual 
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specificity serine-threonine phosphatases that dephosphorylate MAP kinases and negatively regulate 
pathway activation. The loss of negative regulation of MAPK pathway activity, combined with activation of 
MAPK by stimulation of autocrine TGFb signaling induces pathway reactivation during chronic trametinib 
treatment and allows NEG cells to continue to proliferate in the presence of the drug. In response to 
chronic trametinib treatment, cell cycle analysis and crystal violet assays demonstrate that most POS 
cells growth arrest. This is also reflected in the transcriptional response to chronic trametinib treatment, 
where we observe the downregulation of GO terms controlling DNA replication, including multiple terms 
related to DNA helicase activity. However, these cells promote survival by increasing transcription of the 
regulatory subunit of PI3K and PIP3 binding proteins, which stimulates PI3K signaling during chronic 
trametinib treatment.  
Motif analysis of BRD4 peaks upregulated in response to chronic trametinib treatment revealed a 
similar enrichment compared to the acute trametinib response in both POS and NEG subpopulations, 
which is characterized by the specific enrichment of AP-1 family members. Furthermore, motif enrichment 
analysis of H3K27ac peaks upregulated in NEG cells during chronic trametinib treatment revealed few 
highly significant motifs, likely the result of many fewer H3K27ac peaks upregulated in the NEG cells 
compared the POS cells (1017 peaks compared to 3307 peaks, respectively). Interestingly, analysis of 
the upregulated H3K27ac peaks in POS cells identified the TP63 consensus sequence as one of the 
most highly enriched motifs. During chronic trametinib treatment, TP63 expression peaks at Day 14 
before returning near basal expression levels at Day 35, suggesting that TP63 expression may play a role 
in promoting survival during chronic trametinib treatment. Indeed, TP63 has been shown to promote 
survival in mammary epithelial cells by increasing transcription of cell adhesion genes including ITGB1, 
ITGB4, and ITGA6, which stimulates anti-apoptotic focal adhesion signaling (Carroll et al., 2006). We 
observe increased transcription of ITGB4 concomitant with TP63 expression at Day 14, which return near 
basal expression levels at Day 35.  
Drug resistant cells can emerge from a low-frequency subpopulation of slowly proliferating 
persister cells that survive treatment and adapt to the therapy. Hata et al. demonstrated that cells initially 
resistant to targeted therapy can develop secondary genetic alterations that increase proliferation in the 
presence of the drug (Hata et al., 2016). We used two independently isolated trametinib-resistant cell 
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lines to identify key genes that drive the survival and proliferation of drug tolerant persister cells in triple 
negative breast cancer. DESeq analysis demonstrated the chemokine receptor, CXCR7, and its cognate 
ligand, adrenomedullin (ADM) are significantly upregulated in both POS R1 and POS R2 cells. Results 
from RNA sequencing following acute treatment with trametinib shows that these genes are significantly 
upregulated after 24 hours of treatment with 30 nM trametinib. Furthermore, RNA sequencing during 
chronic treatment with 10 nM trametinib demonstrates that CXCR7 expression increases nearly fifteen-
fold from a baseline expression level of approximately 1200 reads at Day 0, to a peak expression level of 
17000 reads at Day 14. Additionally, increased H3K27ac and BRD4 binding can be observed at the 
CXCR7 TSS, suggesting that epigenetic remodeling at the CXCR7 locus contributes to transcriptional 
activation. siRNA knockdown of CXCR7 had no effect in the POS naïve cells, but reduced proliferation in 
POS R1 cells, suggesting that CXCR7 plays an essential role in MAPK activation in drug resistant cells. 
Furthermore, CXCR7 overexpression is correlated with metastatic breast cancer and is associated with 
decreased overall survival and metastatic-free survival in breast cancer patients. Analysis of tumor gene 
expression from 525 invasive ductal carcinoma patients in the TCGA database showed that 16% of 
patients have CXCR7 overexpression, and these patients have significantly worse overall survival 
compared to the normal expression cohort (Wani et al., 2014). Analysis of tissue microarray cores 
following immunohistochemical staining for CXCR in 10 normal, 10 metastatic and 38 invasive ductal 
carcinoma samples shows a significant correlation between CXCR7 expression and aggressive breast 
cancer (Wani et al., 2014). These data indicate that CXCR7 overexpression is associated with poor 
prognosis and survival, and may contribute to resistance to treatment with trametinib. DESeq analysis of 
POS resistant cells compared to the untreated control cells also identified the upregulation of KRAS in 
trametinib resistant cells. Gene expression analysis of breast cancer patients in the TCGA database 
demonstrates that KRAS overexpression is also clinically observed (Cancer Genome Atlas Network, 
2012). siRNA knockdown of KRAS in both the untreated control and POS resistant cells reduces 
proliferation compared to the control siRNA. Furthermore, quantification of RNA-FISH staining of 
untreated control cells demonstrates low KRAS expression, but we observe a wider distribution KRAS 
levels in drug resistant cells, suggesting that the increased expression of KRAS contributes to fitness in 
presence of trametinib. Single cell RNA sequencing of the POS naïve and POS R1 confirms the broad 
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distribution of KRAS expression in the drug resistant cells, as well as subset of cells in the POS R1 
population and POS N population that have similar expression levels. These results indicate that KRAS 
overexpression in the drug resistant cells contributes to proliferation in the presence of trametinib, but the 
broad distribution of expression suggests that there may be other factors, including expression of CXCR7 
that contribute to survival.  
Epigenetic remodeling in response to targeted therapy has been shown to promote the survival of 
persister cells and contribute to drug resistance. Therefore, understanding the mechanisms of epigenetic 
remodeling in response to targeted therapy is key to developing durable therapies for triple negative 
breast cancer patients. Here, we identify unique signaling and epigenetic adaptations to trametinib in the 
mesenchymal NEG cells and epithelial POS cells. MAPK pathway reactivation by downregulation of dual 
specificity phosphatases, as well as upregulation of TGFb signaling can maintain proliferation of NEG 
cells in the presence of trametinib. However, epithelial-specific ETS family members ELF3 and EHF may 
play a key role in the recruitment of the histone acetyltransferase p300 at transcriptionally activated genes 
in the POS cells, which increases transcription of CXCR7 to reactivate MAPK in POS cells. These results 
indicate that trametinib monotherapy may be insufficient to a induce pathological complete response in 






CHAPTER 5: CONCLUDING REMARKS 
Intratumor heterogeneity represents a significant obstacle in the development of durable 
therapies for the treatment of triple negative breast cancer. Gene expression profiling of breast cancer 
has improved the accuracy of patient prognosis and identified novel therapies for each molecular 
subtype, but heterogeneity can confound prognosis and limit the efficacy of individual agents. Single cell 
gene expression analysis demonstrates that triple negative tumors often contain several distinct 
subpopulations. These subpopulations can display a spectrum of phenotypes and demonstrate 
differential sensitivity to targeted therapy. Furthermore, chronic treatment with kinase inhibitors can 
induce the selection of a drug resistant subpopulation (Shah et al., 2012; Yu et al., 2013). Indeed, a 
comparison of the pretreatment biopsy and post-resection tumors of breast cancer patients treated with 
either docetaxel or letrozole revealed that the molecular subtype of the tumor can change during 
treatment (Creighton et al., 2009). Therefore, it is important to understand the mechanisms of resistance 
to targeted therapy in each subpopulation to better design combination therapies that improve treatment 
durability and block resistance.  
In this work, we identified genetically similar epithelial and mesenchymal subpopulations that 
demonstrate differential localization of epigenetic activators at the promoter and enhancer regions of 
transcription factors known to maintain cell identity. RNA sequencing of the two isolated subpopulations 
following acute trametinib treatment revealed genes that were commonly upregulated in response to the 
drug, as well as genes that were uniquely upregulated in response to the drug. We hypothesized that 
epigenetic remodeling in response to trametinib may activate the transcription of genes involved in MAPK 
reactivation and cell survival. Therefore, we identified H3K27ac and BRD4 peaks found in the promoter or 
enhancer regions of upregulated genes, and performed motif searches to identify transcription factors that 
mediate the drug response in epithelial and mesenchymal cells. We identified the enrichment of epithelial-
specific ETS family transcription factors ELF3 and EHF in POS cells, which were not observed in NEG 
cells. Furthermore, we identified increased transcription of ELF3 and EHF in POS cells in response to 
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trametinib treatment. Increased transcription of ELF3 and EHF may increase binding at the promoter and 
enhancer regions associated with ETS-regulated genes to recruit p300 and increase H3K27ac (Figure 
20). Therefore, we will perform ChIP-Seq for these transcription factors to quantify recruitment of ELF3 
and EHF at promoter and enhancer regions of transcriptionally activated genes following acute trametinib 
treatment. Furthermore, I will perform RNA sequencing of POS cells treated with trametinib or DMSO 
control following transfection with siRNA targeting ELF3 or EHF and identify genes that are 
transcriptionally activated in response to trametinib that are sensitive to loss of ELF3 or EHF. Motif 
analysis also revealed that the AP-1 motif was universally enriched at BRD4 peaks upregulated in 
response to trametinib treatment. Interestingly, BRD4 has been found to regulate the expression of AP-1 
family members FOSL2 and JUND, and is enriched at AP-1 binding sites (Najafova et al., 2017). This 
suggests that BRD4 recruitment can stimulate transcription of AP-1 targets to reactivate MAPK signaling 
and inhibition of BRD4 may block this transcriptional activation. However, further bioinformatics analysis 
of BRD4 peaks sensitive to bromodomain inhibitors would be required to test this hypothesis. 
Chronic trametinib treatment demonstrates that epithelial cells remain sensitive to chronic 
treatment while the mesenchymal cells continue to proliferate in the presence of the drug. Analysis of 
gene expression in POS and NEG cells during chronic trametinib demonstrates that in NEG cells, a class 
of genes acutely respond to trametinib treatment, whereas in POS cells this acute response is not 
observed. We identified the upregulation of TGFb and TGFbR in response to trametinib treatment, which 
may reactivate MAPK signaling in the presence of trametinib. To test this hypothesis, I will perform cell 
cycle analysis of NEG cells following treatment with trametinib alone or in combination with the TGFbR 
inhibitor galunisertib. Interestingly, when we examined chromatin remodeling in response to chronic 
treatment in POS and NEG cells, we found that peaks upregulated at Day 14 of treatment remain 
upregulated at Day 35 (Figure 15 A, B, E, and F). These results indicate that chromatin remodeling in 
response to trametinib persists throughout chronic treatment and targeting chromatin remodeling may 
synergize with trametinib treatment for therapeutic benefit. Enrichment of BRD4 at AP-1 binding sites in 
both POS and NEG cells suggests that BRD4 inhibitors may be able to block chromatin remodeling and 
transcriptional upregulation of AP-1 target genes. Previous studies have demonstrated that combining the 





Figure 20. Epigenetic Remodeling in Response to Trametinib Treatment in Subpopulations of Triple Negative Breast Cancer. (A) 
ELF3 (purple triangle) is expressed in POS but not NEG cells and can bind to ELF3 motif (purple line), whereas AP1 (red ellipse) is 
expressed in both POS and NEG subpopulations. (B) Treatment with trametinib increases ELF3 (purple triangle) expression in the 
POS subpopulation and expression of AP1 (red ellipse) in both the POS and NEG subpopulations. (C) Increased binding of ELF3 
(purple triangle) recruits p300 (blue pentagon), whereas AP1 (red ellipse) binding in both the POS and NEG subpopulations recruits 
BRD4 in response to trametinib treatment. (D) Increased recruitment of p300 deposits H3K27ac (blue circle), and increased AP1 




cancer, and slows the emergence of drug resistant cells (Stuhlmiller et al., 2015; Zawistowski et al., 
2017). Future studies may focus on the role of BRD4 recruitment to AP-1 sites and the effectiveness of 
epigenetic inhibitors to block trametinib resistance in POS and NEG cells. BET bromodomains have 
demonstrated utility both as single agents and in combination with kinase inhibitors, and clinical studies 
are currently being organized to test these therapies in breast cancer patients. 
Chromatin remodeling in response to targeted therapy can enhance transcriptional upregulation 
of genes that promote survival and increase drug resistance. We observe the enrichment of H3K27ac and 
BRD4 binding at the promoter and enhancer regions associated with CXCR7, which is correlated with 
increased transcription of the target gene. Knockdown of CXCR7 in POS resistant cells demonstrates that 
upregulation of CXCR7 contributes to survival and proliferation of these cells. Studies of CXCR7 signaling 
indicate that although receptor homology suggests this receptor is Gi-coupled, effector signaling is biased 
to b-arrestin (Rajagopal et al., 2010; Salazar et al., 2014). Additionally, treatment of POS resistant cells 
with the Gi inhibitor pertussis toxin has no effect on proliferation of these cells, further suggesting that 
CXCR7 signaling is biased to b-arrestin. Unfortunately, genetic and chemical inhibitors of b-arrestin 
signaling are limited, which prevents further elucidation of the role of CXCR7 in MAPK activation. 
Currently, there are no commercially available inhibitors of CXCR7, but given the findings in this study, as 
well as the established role in the regulation of proliferation and metastasis, development of CXCR7 
inhibitors may be warranted. 
The development of kinase inhibitors for the treatment of cancer has revealed that intratumor 
heterogeneity and epigenetic plasticity remain significant obstacles for the development of durable 
therapies. Preclinical studies have demonstrated that drug tolerant persister cells emerge during 
treatment with targeted therapy as a result intratumor heterogeneity (Hata et al., 2016). Similar work in 
breast cancer demonstrated that drug treatment can induce epigenetic remodeling in persister cells and 
increase resistance (Risom et al., 2018). Furthermore, our work has demonstrated that epithelial and 
mesenchymal subpopulations can have distinct responses to targeted therapy, which differentially 
mediate drug resistance in these cells. These results highlight the need for novel drug combinations that 
prevent epigenetic remodeling and transcriptional activation in response to targeted therapy. Therefore, 
continued work to understand the mechanism of epigenetic remodeling and concomitant transcriptional 
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activation in response to therapy is paramount to developing synergistic combination therapies for the 
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